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Abstract: 
Clinical research helps in improving patient care and quality of life through 
translation of findings from basic research (laboratory based) into actual benefit to 
patients. The huge advancements in the field of clinical research are accompanied 
by increase in demand for infrastructure, funding and regulations to ensure the safe 
conduct of research. There are many barriers faced by researchers around the 
world that affect the initiation and progress of their clinical research projects and 
eventually lead to wastage of effort and resources. Many studies in literature 
assessed these barriers from the researchers’ perspective. Nevertheless, the aim 
of this study was to identify the barriers as seen by research managers in Qatar. 
The study also had a retrospective aspect where the database of funded projects 
was analyzed for frequency of suspensions and terminations and if they were 
related to the identified barriers. Five research managers from different research 
institutions in Qatar were interviewed for their opinion about the barriers to 
conducting clinical research in Qatar. The interviews were recorded, transcribed 
and a thematic analysis model was applied to generate common themes. The 
major barriers identified could be categorized into four major themes – scientific / 
professional, financial, administrative and regulatory. A retrospective analysis of the 
grants awarded to Hamad Medical Corporation (HMC) confirmed that most reasons 
for the suspensions and terminations were related to these barriers. We believe 
that this study provided very important insight into the barriers faced by researchers 
in Qatar. The outcomes will be communicated to the policy makers in Qatar to 
focus on addressing these issues for a better utilization of the available resources 
and infrastructure to support clinical research in Qatar. The study also paves the 
way for a future study where barriers will be assessed by the researchers. 
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Introduction 
 
Research is defined as “creation of new knowledge and/or the use of existing 
knowledge in a new and creative way so as to generate new concepts, 
methodologies and understandings. This could include synthesis and analysis of 
previous research to the extent that it leads to new and creative 
outcomes.”(Western Sydney University, 2018). It reflects the human nature of 
exploring and finding answers to different existential, physical and metaphysical 
phenomena however in a more systematic and creative way that streamlines their 
effort towards a specific or practical aim or objective. Over the past decades, 
countries have realized the importance of Research and Development (R&D) which 
in turn resulted in huge investments from governments and business corporations 
into different fields like health, psychology, technology, energy and other vital 
elements of R&D. The outcome of these investments positively impacted the lives 
of millions, if not billions, around the world but are these outcomes really equitable 
compared to the invested money, time and effort? Are these R&D initiatives really 
benefitting from the actual investments or is there a “sieve-off” effect in the process 
where significant portion of these financial and non-financial investments are 
“apprehended” due to barriers in the system? 
 
The answer to these questions might vary from one system to another, one sector 
to another, one country to another, however it only varies in the number or severity 
of these barriers. This is because, generally speaking, there is no “perfect research 
system” in the world but each system has its unique pros and cons whether from 
the legislative or executive perspective. 
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Background and Literature Review 
Biomedical Research is one of the fields where countries invest heavily to improve 
the health of living individuals. These investments mainly aim at Research Capacity 
Building (RCB) that augments sustainable and fertile research systems to yield the 
expected outcomes. There are different approaches to RCB that could be initiated 
at institutional, state and national levels. Examples of such approaches are funding 
opportunities, training and development, building facilities and adopting national 
programs to implement the recommendations of different research projects (Pager 
et al., 2012). 
 
According to the World Health Organization (WHO) report in 2017, Gross Domestic 
R&D (GERD) expenditure on health as percent of total GERD ranged between 9% 
and 18% across different WHO regions (WHO, 2018). However there are no 
studies or reports on the actual outcome of these huge investments in this sector 
over the past years. A recent official report (Battelle, 2013) issued by the authorities 
in the State of Qatar forecasts spending around 2.8% of its Gross Domestic 
Product (GDP) for R&D purposes – which is a huge investment, considering the 
fact that Qatar has one of the highest GDPs in the world (The World Bank, 2018). 
Later surveys about the R&D in Qatar reported that the actual spending as of 2015 
was estimated around 0.5% of the national GDP, which was a massive 800 million 
US Dollars (MDPS, 2017).  
 
Biomedical Research in Qatar started to be more organized in the mid-90s through 
a scientific committee at the National Care provider – Hamad Medical Corporation 
(HMC). Hamad Medical Corporation is the largest secondary and tertiary care 
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provider in Qatar (HMC, 2018). The committee evolved into a research center that 
specializes in research administration and support for all research across HMC and 
its nine hospitals. Being the largest clinical care provider, bulk of clinical research 
takes place at HMC, however there are other stakeholders in the Qatari clinical 
research ecosystem like Qatar University, Sidra Medicine, Weil Cornell Medicine 
Qatar and Primary Health Care Corporation. All these stakeholders including HMC 
fall under the umbrella of the Ministry of Public Health when it comes to national 
governance of the clinical research in Qatar. 
 
HMC research center currently has its own funding opportunities on a routine as 
well as competitive basis that is open to HMC researchers and their collaborators. 
Another important source of funding is the Qatar National Research Fund (QNRF), 
which is the national research funding agency that funds research grants aligned 
with the Qatar National Research Strategy (QNRF, 2018).  
 
QNRF has different funding programs that cater different levels of researchers 
ranging from Undergraduates to post-doctoral scientists and senior researchers. 
These funding program cycles are launched annually with minor changes to 
address the changing research priorities within Qatar and the region. Over the past 
years, HMC has received more than $70 million in funding through different QNRF 
funding programs. The major funded areas include diabetes and metabolic 
disorders, cancer, Cardiovascular diseases and public health.  
 
However, like many other research systems around the world, there are barriers to 
implement clinical research in Qatar smoothly and efficiently that have been 
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observed over the past years. In this research study, our focus was barriers to 
implementation of clinical research which means the actual conduct of research or 
execution of research projects by researchers. 
 
The existence of barriers to implement research – or clinical research to be specific 
– has been reported in quite a few studies in the literature. A systematic review 
identified four barriers to implementation of trials in Trauma surgery (Perry et al., 
2014). One of these barriers was the surgeons’ beliefs regarding the trial 
methodologies and absence of “equipoise” within the surgeon. Equipoise usually 
means a balance or counter balance of something but in this case, it means the 
surgeon’s favoring opinion of one treatment over another and this in itself is a 
barrier for the surgeon to participate in research. The review also explored other 
barriers like disease barriers, process barriers and patient barriers. They concluded 
that even if high quality research was performed, there could be other barriers that 
hinder the transformation of this knowledge into clinical practice. Another extensive 
review assessed different barriers that are specific to the conduct of Randomized 
Clinical Trials (RCTs) (Duley et al., 2008).They identified seven barriers that were 
common to independently conducted RCTs. The first barrier was lack of funding for 
large trials and the high cost for setting up of low-cost trials. Large trials require 
huge funding and it becomes challenging for independent trials that are not 
sponsored commercially to secure these funds due to scarcity of available 
opportunities. In most cases, funding organizations are disease specific and do not 
accommodate all the major public health domains that do not fit their profiles. Other 
funding organizations are very competitive and the review process are so extensive 
and prolonged that affects the implementation of these trials. On the other hand, 
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low-cost clinical trials also require high cost for setting up sometimes almost 
equivalent to the cost of the actual trial itself. This is due to the increased 
complexity in the regulatory requirements of these trials that involve submission to 
different review and ethics committees and each committee requires a substantial 
review fee. Other regulatory requirements also require set up fees like storage 
spaces, offices, binders, annual reviews etc. Another issue related to lack of 
funding is inadequate infrastructure and facilities for conducting large trials. This 
has led to a new trend where trials are being conducted in low and middle income 
countries due to the relatively low setup and running costs compared to high 
income countries. Such trials may not produce the required results mainly if the 
research questions are not relevant to the target population in these countries. The 
second barrier identified in the review was complexity of the regulations preceding 
recruitment into the trial. The main issues underlying here are the multiple 
committees involved in review of clinical trials, the amount of time and effort to 
address the concerns of each committee, contract negotiations and the additional 
regulations for research involving drugs (IND review). The third barrier was 
excessive monitoring for adherence to the trial protocol. They discussed how 
applying the same standards for trials involving new drugs and trial testing a 
generic drug already in the market was adding stringent burden to the trial setup 
and lack of alternative methods for monitoring. An interesting aspect also discussed 
here was their suggestion to study the carbon footprint of monitoring i.e., the carbon 
emissions for each monitoring trip. The fourth barrier focused on the complexity of 
the trial procedures itself like the long consent forms, recruitment, complex 
reporting requirements and multiple protocol amendments for each minor revision. 
The fifth and sixth barriers were related to conservative interpretations of privacy 
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laws and lack of training and education about trial methodology. The last barrier 
assessed in the review was the lack of evidence on conducting trials and how 
common procedures for all trials – regardless of their research question – was not 
the ideal approach to tackle this issue. “Invisible” barriers to clinical trials have been 
studied with respect to opening of oncology trials in a single research network at 
Vanderbilt, USA (Dilts & Sandler, 2006). A comparison study was done to outline 
the possible differences between 2 diverse settings - a University Medical Center 
(VICC) and community-based oncology network (VICCAN). Mapping of existing 
processes for opening an oncology clinical trial and timing analysis for time required 
was performed. The process was broken down further into different steps like 
preparation of documents, discussion with team/ department, budgeting and final 
preparation for initiation of the trial. There was no significant difference in the 
process maps of both settings with regards to the number of steps, however, the 
number of committees/ individuals involved in the VICCAN were much less than 
VICC (almost 5 times less). Nevertheless, the timing analysis showed that actual 
time taken to open a trial did not differ much in both settings. A deeper analysis of 
the underlying reasons to these delays showed that the maximum time consuming 
step was the grants and contracts and not the IRB or scientific review – contrary to 
the usual belief among investigators. The study also had a unique finding that a 
good number of opened trials had poor accrual rates which raises concerns about 
“wasted efforts” at the different review stages for poorly planned trials. A short 
article describing the outcome of discussions by a working group convened by FDA 
and Duke University to identify barriers to conducting large RCTs stressed that 
these trials must be simple – financially and design wise (Eapen et al., 2017). 
FDA’s initiatives in this regard were described further that included two guidance 
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documents and a new rule regarding reporting of unexpected adverse events. The 
article also called for close collaborations between researchers and clinicians 
towards a health system that represents bench to bed research models.  
 
There are quite few studies that covered the barriers from the researchers’ 
perspective. Faculty members of Birjand University of Medical Sciences in Iran 
identified financial, organizational-managerial barriers and professional barriers as 
the most significant barrier to research (Ehtesham et al., 2017). Other barriers 
reported in this cross sectional study included facilities, individual and scientific 
barriers. A cross sectional observational study was conducted on Allied Health 
Professionals (AHP) teams in Australia to evaluate the motivators and barriers to 
research in these teams (Wenke et al., 2017). The survey tool used was the 
Research Capacity and Culture tool (RCC) which is a validated questionnaire that 
measures 3 domains of research capacity – organization, team and individual 
(Holden et al., 2012). Six major barriers were identified by the AHP team members 
including lack of time, clinical workload, lack of funds, poor administrative support 
and shortage of support staff. However, there was no significant correlation 
between the reported barriers and the research activity of these teams in terms of 
funding received, approved proposals and research output. On the other hand, 
there was stronger association between motivators like career development, job 
satisfaction, skills development etc. with the research output and higher funding 
received. Research barriers were also identified by experts attending educational 
seminars in Mazandaran University of Medical Sciences in Iran (Ataee et al., 2015). 
A survey questionnaire with 2 parts related to individual characteristics and 
personal/ organizational barriers was distributed to the attendees of these seminars 
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between 2007 and 2009. Among the individual barriers the most common barriers 
were lack of time and motivation. As for the organizational barriers, the most 
significant were research conducted by authorities, lack of funding and research. In 
another study, radiologic technologists registered with the American Registry of 
Radiologic Technologists (ARRT) were surveyed about perceived needs and 
barriers to research (Fauber & Legg, 2004). The survey also includes questions 
about their opinion regarding professional emphasis on research. Reported barriers 
included training, access to equipped facilities, funds and support personnel. 
Around 80% of the respondents agreed on the lack of available time for research 
and the priority of research in their practice. However they also had a positive 
attitude towards research as they agreed about its importance for professional 
growth.  
 
Barriers to involvement of front clinicians were also identified in a cross-sectional 
study among clinical members of the American Society for Marital and Family 
Therapy (Sandberg et al., 2002). The study team mailed the clinicians requesting 
the participation of their clients in a hypothetical research project and asked the 
clinicians if they would be willing or not to participate in such a project and what 
could be changed to persuade them into participation. They were also asked about 
what could make the research more applicable to their practice. For the first couple 
of questions, the responses were analyzed and further coded into 4 categories – 
time/ money restraints, outside limitations like restrictions from employers, client 
concerns like confidentiality or risks and ambiguity regarding their role in the 
proposed study. As for the third question, the responses were again analyzed and 
further coded into another 4 categories – time/ convenience, relevance to their 
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discipline, personal/ professional barriers e.g. lack of support groups and design 
and presentation of the study. The authors suggested that clinicians must be 
involved in the conceptualization and design of studies to ensure relevance to their 
discipline. It was also suggested that clinicians must be compensated for their extra 
time and effort in these projects. Collaborations between academics and clinicians 
were also encouraged to overcome most of these barriers. 
 
The topic has been addressed from the students’ perspectives as well at Taibah 
Medical College in the Kingdom of Saudi Arabia (Noorelahi et al., 2015). A cross 
sectional survey was conducted among older medical students and included 
demographics, attitude towards research, practices and barriers to participate or 
conduct research. The respondents identified four major barriers like absence of 
adequate facilities, lack of interest by the faculty and guides as the main barriers to 
conduct of research, in addition to unavailability of patients. However, there was a 
positive overall attitude among the medical students towards research. The 
researchers also reported that lack of facilities and sample patients would be 
addressed soon after the (under-construction) facilities at their university would be 
up and running. Another research study elaborated on the bridges and barriers to 
integrated interdisciplinary research among graduate students (Nielson-Pincus et 
al., 2007). The study involved series of workshop exercises involving graduate 
researchers and identified three themes of bridges and barriers – individual, 
disciplinary and programmatic. Each theme had distinct categories with underlying 
issues and respective bridges to these issues. Individual barriers included vision, 
dedication and problem solving skills as the main categories. Four categories of 
disciplinary issues were idiosyncracies, scales and units, models and frameworks 
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and focal themes. At the programmatic level, the three categories were framework, 
mentoring and training/ resources.  
 
On the other side of barriers to research implementation, there are other barriers to 
Research Utilization (RU). These barriers apprehend the implementation of 
research findings into actual practice, policies or programs that would benefit the 
target populations. Numerous studies were conducted to study barriers to RU in 
different settings (Kajermo et al., 2000 and Lyons et al., 2011).  
 
Implementation research is the scientific study of processes used to implement 
health policies and programs by addressing challenges through real time 
application of gained knowledge through systematic methods (Theobald et al., 
2018). It aims at identifying the strengths and weaknesses of the current system 
and different ways to improve implementation and maximize utilization of the 
available resources. WHO has recently adopted this initiative for many of its 
programs including disease eradication, enhancing service delivery through 
management improvement and empowering beneficiaries (WHO, 2013). The topic 
has also been discussed by Peters et al., 2013 who encouraged mixed methods of 
qualitative and quantitative studies as best means of implementation research. 
 
Almost all studies regarding barriers to implementation of clinical research available 
in literature and described above are either review papers or studies that assess 
barriers from the researchers’ perspectives. However published work on a similar 
topic from the perspective of research managers and executives is scarce. One 
study assessed the barriers to execution of cancer clinical trials from both 
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perspectives – researchers and managers. A cross sectional survey of oncologists 
together with semi-structured interviews of oncology leaders was conducted in a 
cancer research network under National Cancer Institute (NCI) (Somkin et al., 
2005). The overall attitude of oncologists towards supplying support for research 
trials was positive. Barriers were classified into large, somewhat large and not 
barrier. Lack of support staff and dedicated time for research were the most 
frequently reported large barriers whereas majority of the oncologists did not see 
funding as a barrier. As for the infrastructural support, the majority of them agreed 
that the medical school education did not prepare them adequately to conduct 
research and the clinical oncology program did not help much either. However, they 
acknowledged the support from the local research department, fellow physicians 
and data managers in their organizations. There were also issues regarding 
identification of potential participants in the trials were lack of support from the 
organizational staff and resources was raised. As for the oncology research 
managers/ leaders, they were interviewed about issues related to finance and 
resources. Most believed in the importance of trials with least (negative) cost effect 
to actual patient care. Other leaders discussed about better communication within 
the network and with NCI and more involvement in the design of the trials. Overall, 
the study showed the different perspectives of oncologists in comparison to the 
leaders on how to conduct clinical trials. While oncologists bemoaned lack of 
support staff and time for research, leaders had a different perspective of the 
barriers to ensure that the costs of additional tests and protocols were controlled 
and that conduct of research trials must not affect the access of patients to their 
usual medical care.  
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Another component of this study was to retrospectively review the records of the 
grants received by HMC from QNRF and track the suspended/ terminated studies 
with the reasons for these setbacks. Since the funded grants are closely monitored 
by QNRF through periodic reports and site visits, they are subject to grace periods, 
suspensions and even terminations in extreme cases. These decisions are based 
on the assessment of the progress reports submitted by the Lead Principal 
Investigator (LPI) and site visits by QNRF project managers. These managers 
share their concerns with the LPI or in some cases raise it directly to the QNRF 
review committee for a decision in this regard. The decision is communicated to the 
Authorized Research Office Representative (AROR) of the awardee institution in a 
letter outlining the reasons for suspension or termination. The letter usually dictates 
the required actions to revoke the suspension or appeal the termination decision. 
However, suspensions and terminations can also be initiated by the AROR of the 
awardee institution. This could happen due to institutional findings, administrative 
issues or arising of unfavorable conditions that would affect the conduct of the 
research grant at that time. The final decision is always subject to QNRF’s review 
and approval. Suspensions are provided for a maximum of 90 days after which the 
project gets terminated by default, unless further extension is granted on 
exceptional grounds. On the other hand, there are 2 types of terminations – for 
convenience and for cause. The first can be initiated by either party and is applied 
for obvious reasons stated in the master agreement whereas the latter is initiated 
by QNRF alone. It is always the duty of the awardee research office to 
communicate these decisions to the sub-awardees, if any. The main reason for 
reviewing these records was to extract information about the frequency of 
suspensions and terminations in the awarded projects to HMC and also identify the 
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main reasons for these adverse decisions by QNRF. The reasons would then be 
classified into categories and these categories would be compared to the themes/ 
categories generated from the analysis of the interviews to confirm the existence of 
the barriers identified by the managers in their interviews. Since the routine 
proposals managed at the research center are not scrutinized as thoroughly as the 
QNRF projects, it was ideal to select QNRF awarded projects for this descriptive 
analysis.  
 
Rationale of the study 
No other studies in literature, to the best of our knowledge, have assessed barriers 
to conduct clinical research in any setting from the managers’ perspective. Hence 
this study was the first study in the region and possibly the world to identify these 
barriers from a new perspective. We believed that by doing so, we would not only 
identify barriers but possibly identify any gaps with regards to funding availability or 
resource management in the viewpoint of the researchers and managers. 
Elimination of such gaps would promote a more productive research culture as the 
targets would be clear to both sides of the equation in a research ecosystem. This 
would help not only in enhancing the conduct of clinical research but also in better 
utilization of this knowledge thereby contributing positively to the RCB initiatives in 
Qatar. The findings of this study would also help streamline efforts across all 
stakeholders and all levels thus contributing to better exploitation of the available 
research infrastructure and funding in generating the expected research output.  
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Research Questions 
 
The questions that were expected to be answered at the end of the study are as 
follows: 
1) What are the barriers to conducting clinical research in Qatar as seen by 
research managers? 
2) What are the barriers to conducting clinical research in Qatar as reviewed in 
the existing QNRF funded grants? 
3) How are these barriers affecting the implementation of clinical research in 
Qatar? 
4) Are these barriers specific to the Qatari research systems? 
5) What is being done to overcome these barriers? 
6) How are funded grants affected by these barriers? 
 
Specific Aims 
Specific Aim 1: To identify the barriers to implementation of clinical research in 
Qatar from the research managers’ perspective. 
 
Specific Aim 2: To retrospectively assess the recurrence of suspensions/ 
terminations in the QNRF funded projects to HMC and the reasons for these 
setbacks 
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Methodology 
 
Design 
This is a pragmatic study that involves mixed methods approach. Firslty and due to 
scarcity of knowledge in literature about the managerial perspective of this topic, an 
interpretivist research model appeared to be the best approach for implementing 
this study since it includes an iterative process of interpreting the data and 
outcomes for the interviews and the qualitative analysis performed. On the other 
hand the positivist approach is also used in relation to the quantitative analysis, 
which deals with retrospective data that the researcher has no influence on.  
There was no hypothesis as such but rather a tentative theory based on the 
literature review. The pragmatic model is also considered ideal for mixed design 
studies (Williamson and Johanson, 2018). Hence our study design was observational 
cross sectional and retrospective, including mixed design with both qualitative and 
quantitative components. The study had 2 parts: 
 
Qualitative study: The first aim of the proposed study comprised of face to face 
semi-structured interviews with the research managers and executives of different 
stakeholders in the research community in Qatar. The key personnel to be 
interviewed were identified through their known profile in Qatar since the research 
ecosystem is relatively small considering the small geographical size of the country. 
These key personnel were contacted through email with an invitation to participate 
in this research study (See Appendix 3). The email also included an information 
sheet (See Appendix 1) with all the required details of this study that would be of 
importance to them as participants and the interview method. The participants were 
21 
asked to sign a consent form after reading the information sheet (See Appendix 2). 
They were also informed through the sheet that their interviews will be audio 
recorded and transcribed anonymously for the purpose of thematic analysis later. 
Confidentiality was assured and the interviews were scheduled according to their 
convenience. The interview guides were semi structured constituting of open-ended 
questions prepared by the research team after extensive literature reviews and 
inputs from experts in the field (See Appendix 4). The questions included 
background information about the participants (age, education and role), their 
experience in clinical research, to describe the research support in Qatar in general 
and specifically in their institutions, how much funding is used efficiently, research 
space and time allocations, research barriers and what solutions were suggested or 
taken. The discussions were moderated in English as a preferred mode of 
communication since all the managers had their higher education in English.  
Participants 
The interviews included the following personnel that represent the clinical research 
community in Qatar: 
 HMC  
 Ministry of Public Health  
 Sidra Medicine  
 Weill Cornell Medicine Qatar  
 Qatar National Research Fund  
 
Four managers were in the age group 50 to 60 years, one above 60 and one below 
50 years. Except for one, all managers had educational backgrounds that included 
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both clinical and administrative degrees with sufficient experience in both fields as 
well. Two of them were still practicing clinicians while others focused on 
management only. One manager was relatively new to the clinical research 
ecosystem in Qatar and joined almost a year back but all other managers had at 
least 4 years of experience in the clinical research management in Qatar. 
 
Each interview lasted for 30-45 minutes and the interviewees were asked questions 
about the clinical research environment in Qatar, strengths and weaknesses, 
barriers to successful implementation and proposed solutions.  
 
Quantitative Study: A retrospective observational review of the QNRF funded 
grants to HMC was done for the second aim of the study.  The information is 
available on the QNRF database that is accessible by the research office at HMC. 
Further investigation of the project specific folders was done to ensure that the right 
reasons for the suspension or termination were captured. The range of review 
included all studies awarded to HMC from the first cycle until the ninth cycle. The 
latter awarded cycles are relatively new and started as recent as last year hence 
there are no issues with any of them yet.  
 
A separate data sheet was created with the number of awarded grants per cycle, 
number of suspensions per study and per cycle, terminations and reasons for the 
suspensions and terminations.  
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Ethical Considerations 
Approvals were obtained from the relevant committees at Kingston University 
London and Hamad Medical Corporation since the study was being conducted in 
Qatar (See Appendix 5). All participants were presented with an information sheet 
along with the invitation email and consent form before starting the interview. The 
information sheet clearly described the goals of the study, assurance regarding 
confidentiality and that participation was voluntary giving them the option to 
withdraw at any point. They were also given the freedom of not answering any 
question that they were not comfortable with. However, none of the participants 
declined any question during the interview. A debrief sheet was also provided to 
each participant at the end of the interview (See Appendix 6).  
 
The recordings and transcriptions were stored on the researcher’s personal laptop 
in a password protected file that only the Researcher has access to. The 
transcriptions were anonymized by removing any reference to the name or place of 
work of the interviewee by replacing these identifiers with study specific codes once 
the final version of the transcription was verified (See Appendix 7). Only the 
anonymized transcriptions were stored for analysis. 
 
The study was conducted in full conformance with principles of the “Declaration of 
Helsinki”, Good Clinical Practice (GCP) and within the laws and regulations of 
MoPH in Qatar. The data that was shared with the Mentor at Kingston University 
London was in accordance with the UK Data Protection Act (2018).  
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Statistical Analysis 
The study explored the different barriers to implementation of clinical research in 
Qatar. The data gathered from the participants' interviews was transcribed and then 
analyzed thematically using the following steps (Braun & Clarke, 2006): 
1. Transcribe verbal interviews into verbatim transcripts. 
2. Read through the transcripts to quality check them against the original verbal 
interviews. 
3. Generate initial codes from the transcripts making sure to code for potential 
themes or patterns, remembering that individual data can be coded many times.  
4. Search for themes in the initial coding, grouping codes together under broader 
themes. Some codes will become central themes, while others will be allocated 
to sub-themes or remain codes within a theme or sub-theme.  
5. Review and refine themes to ensure that there is sufficient data to support them 
and if not seek to combine themes under an over-arching theme. Understand 
how each of the final themes links and work together with each other; 
understanding partnerships and causal relationships between them. 
6. In case interview constitutes of data that does not come under the suggested 
themes we will build up new themes accordingly.    
7. Define and refine the theme names by reviewing the data collated behind each 
theme name and where necessary adjust the name to accurately reflect the 
data. 
 
For the quantitative part, descriptive statistics such as frequency and percentages 
for collected data were performed in the form of number of QNRF projects per year, 
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number of suspensions or terminations per project and per cycle and the reasons 
for these. 
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Results 
 
Qualitative Study: 
Five managers were interviewed for this part of the study. After transcribing the 
interviews (See Appendix 7), the thematic analysis model explained above was 
applied. Barriers from each interview were identified, listed, coded and grouped into 
sub themes and further condensed into four main themes. These themes included 
all the barriers identified in the interviews (See Table 1 for summary of these 
barriers according to themes and sub-themes). 
 
Professional/ Scientific Barriers 
There were mainly three categories or sub-themes under this theme that were 
grouped into one.  
The first one was training that includes lack of proper training for clinical 
researchers and the administrative staff and its underlying issues. The second sub-
theme was population – both researchers and research subjects – were transient 
and hence creating or retaining a critical mass of clinical researchers on the long 
term was not possible. The third sub-theme was the personal barriers for 
researchers like lack of protected time, clear assignment of roles and the 
ambivalent vision for research in the country. 
Five out of six managers interviewed agreed that there was no protected time for 
clinicians and this was the main professional barrier. Lack of protected time had 
other implications that hindered self-development of clinicians as researchers: 
“…the issue of lack of protected time for researchers because it is a real problem 
where the clinicians are expected to provide research output and spend time 
conducting research but at the same time expected not to compromise their clinical 
duties, which is of course their main duty as clinicians.” (Manager 1) 
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 “…there is a group of clinicians who are extremely busy and they are good at 
research and want to it but they don’t have protected time.” (Manager 2) 
 
“…we are getting people who are more passionate about research itself but the 
problem with that is that they are clinically busy so they cannot really focus on 
doing research.” (Manager 3) 
 
“Physicians are very keen and interested in conducting research however there is 
no protected time for them to conduct research. Places like PHCC and HMC don’t 
provide protected time to their physicians for doing research. Therefore, it does 
affect their ability to submit and work on these proposals.” (Manager 4) 
 
“The clinicians have so many beautiful ideas and they are sincere to make it 
happen but they do not have time and I cant blame them because their first job is 
the clinical service.” (Manager 5) 
 
The same majority also identified lack of research specific education and 
training as a barrier to conduct clinical research in Qatar. The reasons they 
mentioned were absence of sustainable training programs and induction training for 
the researchers when they join an institution in Qatar: 
 “There is a lot of education and training that needs to be done in terms of what 
clinical research looks like, how they are reported, SAEs, AEs, pathways that can 
be harmonized.” (Manager 3) 
 
“There has to be a very well-established training and education program to keep 
reminding a clinician about the ethics of research.” (Manager 4) 
 
“…most of the them are trained to be clinicians and not researchers. In the modern 
medical degrees, a lot of research component is included within the education and 
it’s the approach in getting knowledge that gives them research experience. Such 
systems give the freedom of being creative in doing things in a new way not done 
by someone earlier because each one of us has their own unique way of thinking 
and applying. In the US, no matter where you come from, you need to complete a 
rigorous training before you start any research even when you move from one state 
to another. I wish we had something similar here in Qatar and if we have it now, I 
am not sure about its quality.” (Manager 5) 
 
Three managers also highlighted the issue of the importance of scientists and 
research support who would complement the role of clinicians in conducting clinical 
research studies. These resources are limited when it comes to clinical research 
support groups like coordinators, nurses and academic scientists: 
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“…from the point of quality of research being done, there is huge enthusiasm for 
research but I think we are yet to have a proper critical mass of really experienced 
researchers” (Manager 1) 
 
“…So clinical research teams are not doctors who see patients but instead trained 
to do and support research while in HMC I don’t think we provide that to our 
researchers… In my opinion I think the PI needs to spend more time doing the 
science than spending time on the operational part that is handled by other trained 
personnel like CROs. To be more efficient as an organization, we need to have our 
own core group of support that could be tapped into by different researchers.” 
(Manager 2) 
 
“Because the clinicians collaborate with scientists who take care of all the writing, 
designing and submissions and clinicians are only recruiting the subjects.” 
(Manager 5) 
 
One manager stated a very important problem that could be a deciding factor for 
clinical trials with long term follow up or longitudinal studies - transient population. 
Since Qatar is a country where expatriate population is very high, it becomes 
challenging to retain a recruited participant for a longer duration: 
“…the population here is mostly transient and expatriate. It is therefore hard to have 
long term clinical trials because their jobs may not be secure to allow long term 
follow up.” (Manager 3) 
 
Managers also called for clear distinguishing between the roles of clinicians and 
clinician scientists based on their contracts and responsibilities: 
 “The biggest challenge here, and I believe it’s not specific to HMC, is that the 
majority of the academic health systems find it difficult to distinguish between 
clinicians, clinical scientists and clinical research teams.” (Manager 2) 
 
“Everybody’s job description must have outlined portion for clinical duties, research, 
teaching and administration. If this happens then research will become a part of 
their job and if it’s their job then they will more likely do it better.” (Manager 3) 
 
Administrative Barriers 
Processes, management and governance were the sub-themes identified here. 
Processes includes operational and logistical issues like hiring, procurements, 
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maintenance and sustenance of resources. Lack of a focused strategic vision, 
leadership stability and communication were all grouped under management. The 
third sub-theme, governance, includes issues like data access and institutional 
framework.  
The issues regarding processes and operational barriers at the institutional level 
like hiring and managing research were commonly discussed. In some cases, these 
procedures were described as repulsive while others said it added to the already 
existing problems: 
 “One of the issues is the mismatch between operational, capital and manpower 
expenses. What we see within AHS-MRC is the same what HMC experiences 
every year. We have a number of posts that are not occupied and hence we have 
programs and funds unutilized because of that. Last year we had developed a bid 
for a clinical trials unit and we were assigned a huge operational expense but then 
no posts were approved so we ended up handing back the operational expense 
which would imply that we didn’t need it but the truth is that we needed the posts to 
use it.” (Manager 1) 
 
“The biggest challenge is the previously, and still, existing systems which are 
repulsive to conduct research at HMC. That translates into challenges in 
recruitment, procurement and career planning for researchers, recognition of 
research achievements – all these are not conducive to research at HMC.” 
(Manager 2) 
 
“These are all operational issues and if you have the right manager who ensures 
that all obstacles are removed, there will be progress. So, it’s not about the funds 
you have but about how it is managed and how you have the right person in the 
right seat based on their qualifications and skills. In most cases here, there is a 
mismatch where we place the right person in the wrong seat.” (Manager 6) 
 
Lack of governance structure or their weak implementation was discussed by two 
managers. They had the view that strong governance system was either absent or 
misunderstood and hence not effectively implemented: 
“Another important barrier is the research governance and by governance I don’t 
mean the policies as such because the policies are very well drafted but then the 
personnel allocated to ensure proper implementation of these policies and 
guidelines is just not sufficient. We don’t have enough hospital research officers or 
clinical monitors for having the site initiation visits or monitoring of ongoing research 
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projects. We need to be pro-active in avoiding compliance issues but the available 
research personnel only allow us to be reactive to a certain limit.” (Manager 1) 
 
“There is lack of understanding of the governance roles because the management 
depends on the feedback of the “violators” to review the performance of the 
governance officers.” (Manager 6) 
 
Three managers mentioned that one of the major barriers to design and implement 
clinical research in Qatar was the limited epidemiological data and the difficulty 
in accessing it. The issue was not new, according to them, however limited steps 
were taken to address it: 
“…we must seriously consider having a national research data registry that could 
provide real and reliable data to the researchers in Qatar and collaborators who 
wish to implement studies here. The problem currently is that we don’t have reliable 
statistics about the patient population or the clinical burden of different diseases in 
Qatar and this is critical.” (Manager 1) 
 
“Initially, the system here was very conservative when it comes to data access 
because there was no Cerner available and any access for data needed many 
stages of approval. To go around this, the researchers used data from outside 
Qatar, which could sometimes be unreliable, to build their proposals and this is not 
right. Lack of epidemiological studies relevant to Qatar was a very big challenge. 
Even after we started having studies, there were issues with access to the data 
from these studies.” (Manager 5) 
 
“Not a single health institution in Qatar uses prescriptive analytics in healthcare 
which means that we are using basic analytics for the billions of dollars invested in 
the top-notch facilities. If we run those analytics and generate massive data, this 
would then cause experts from Harvard and MIT to come and work here because 
we would be sitting on a gold mine of research data.” (Manager 6) 
 
Absence of centralized leadership for research management and hence the 
absence of long-term strategic investments was also identified in a couple of 
interviews. Unclear KPIs and measures that would otherwise help in the strategic 
planning were also stated as a barrier: 
“Qatar could do better than compared to other places because in places where 
there are regular elections, programs are encouraged for short terms but then the 
political system here is more stable and can plan for the long term.” (Manager 1) 
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“I honestly believe there is a major gap in understanding our KPIs and how do we 
measure this return on investment” (Manager 6) 
 
“Here we see a lot of redundant work but no focused areas... We have to define our 
trajectory, mission, vision to be fitting into the needs of the country. We have all of 
these things in paper but not in the reality.” (Manager 6) 
 
“The only thing missing for research across Qatar is proper management and 
oversight. I am referring to the overall cross-institutional strategic management of 
the research pot…The right question that I would like to answer is what does it take 
Qatar and my institution in particular to be an elite. I believe it’s just the last mile – 
the leadership.” (Manager 6) 
 
Financial Barriers 
Most issues identified in this theme were categorized under funding and 
infrastructure.  
Funding included both sides of the spectrum as some managers opined that the 
funding pot for research was not sufficient while others believed that research was 
generously funded but poorly managed. There were also concerns about the high 
costs of research related services and returns on the funds invested in research. 
There were other issues related to poor infrastructure like absence of core support 
facilities, lack of research space, and optimum utilization of the available physical 
resources. 
All managers identified infrastructure as one of the barriers for clinical research 
but some referred to human infrastructure while others to space and other facilities: 
“Lack of personnel is again an issue if we are aiming to implement clinical trials 
because the available staff and expertise is good enough to support the clinical 
service but not research trials… We also have issues for research space to 
accommodate the different research trials happening across HMC.” (Manager 1) 
 
“The footprint for research is small compared to the size of the organization. 
Another challenge is that the research space is scattered all over the organization 
in different buildings and facilities” (Manager 2) 
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“When we do a study at a clinic, the rooms change frequently and we can’t have a 
stable environment to do it. Most countries have clinical research center geared up 
with nurses and it is done in a slick way.” (Manager 3) 
 
“Most of the hospitals such as HMC and Sidra are in the process of developing their 
infrastructure to build clinical research units however there are lots of barriers when 
it comes to budget, human capacity etc. so the progress in this area is very slow.” 
(Manager 4) 
 
Few managers listed funding or restrictions on use of current funding as a 
barrier. Three of them agreed that there was a gap in the reality and the expected 
outcomes based on the financial investment in research while another manager 
had concerns about the restrictions by the funding agencies on using the granted 
funds when it comes to re-allocation of costs, carry over etc.: 
“There could be a 5-year plan to transform HMC into an academic health system 
with research at its core but this needs a lot of work that the higher management 
and senior clinicians fail to see this gap… One of the main issues that we face for 
funding in general is being underspent but then this has other reasons. For 
example, if we budget for a clinical trial but then the team is not able to recruit the 
required personnel due to the stringent procedures, the outcome is underspending 
but this does not reflect the true picture because the underspending was due to 
these barriers. The financial status in the country is now more stringent and hence 
any investment needs outcomes to justify it to the management.” (Manager 1) 
 
“…there is a gap in the expectation about what that fund could be translated into or 
what output could be produced through that investment… The expectation is high, 
the investment is significant however the means of meeting those expectations 
when it comes to having the right programs and right support services needed to 
implement to reach those outcomes are not properly in place.” (Manager 2) 
 
“We have a limited funding because when there is cap, you can’t answer all the 
questions your research was exploring... Similarly, when there is a budget cutdown 
from the awarded grants by the funding agency, they can’t do that for clinical 
research because it is not like basic science where you can adjust to budget 
revisions by doing less experiments.” (Manager 3) 
 
Two managers mentioned a couple of issues related to funding which could be 
specific to Qatar. One was the relatively high costs for carrying out animal 
experiments compared to costs for similar experiments outside Qatar while the 
other was about cost of recruiting qualified personnel for funded projects: 
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“if you are hiring a post-Doc, then you need to pay for their housing, education, 
leaves etc. in addition to their salary so a post-doc in the US might cost you 60,000 
dollars but here it is around 200,000!” (Manager 3) 
 
“Also, the cost is unusually high compared to the cost of performing the work 
outside and I am not sure about the reasons behind this.” (Manager 5) 
 
Any investment, including that on research, needs to have some outcomes to be 
reported against the invested funds. This matter was discussed by three managers 
who believed it is important to measure and report the return on these investments 
to show efficient spending of the allocated budgets: 
“The other issue that we should be able to prove that we are effectively spending 
what we receive… we have to also be ready for a time where the higher 
management could change so we must have this data to convince anyone who 
would take over then.” (Manager 1) 
 
“However, when we look at the funders, they have to report somewhere higher 
about the outputs of this funding. Outputs can be publications, new IP and all that 
but science does not always produce these outputs, not right away at least.” 
(Manager 3) 
 
“When it comes to return on investments, we need to understand how much we are 
getting out of the generous spending. I honestly believe there is a major gap in 
understanding our KPIs and how do we measure this return on investment.” 
(Manager 6) 
 
Indirect Costs (IDC) associated with funded projects were discussed by two 
managers who believed that these costs required more assessment regarding its 
applicability to the system here and the best way of managing these costs: 
“However, I don’t see how this could be applied in the system in Qatar and hence 
there should be better ways to manage the IDC to be used more effectively.” 
(Manager 1) 
 
“the IDC until recently was being used for non-research purposes. It is very 
unfortunate that it was used for supporting other departments not involved in 
research but this is slowly changing now. The concept of “chopping off” funds for 
non-research purposes must be stopped and we must pursue better utilization of 
these funds into research purposes.” (Manager 2) 
 
Regulatory Barriers 
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Legal framework and Institutional Review Boards (IRBs) were the main sub-
themes under regulatory barriers.  
Managers expressed concerns about the lack of legal framework to support 
research in the country and most laws were either criminal or civil but no clear path 
as such for research related matters. The policies at the highest level also required 
refining as many policies were “imported” and did not cater the needs of the 
research environment in Qatar. Managers also seconded the negative feedback 
they receive from their researchers about inconsistency in the submission process 
for different IRBs at each institution and how each IRB had their own set of 
conditions, which were at times conflicting with conditions of a collaborator’s IRB. 
Hence, regulatory barriers were identified at the national and institutional level.  
For the legal framework, two managers discussed that it required extensive work 
to be conducive for the clinical research, although it was developed recently. There 
were concerns that the adopted framework was not totally suitable for the clinical 
research environment in Qatar: 
“Again, this takes us back to the American system being replicated here but unlike 
here, they have many startups or sponsors for research projects and researchers 
are actively holding shares or promoting these companies.” (Manager 3) 
 
“There is not much maturity in the legal system for research. As of today, I don’t 
see any legal framework for research. We reviewed a draft a couple of years back 
but I am not sure if it was implemented but then it is important before we release 
millions of dollars that we have a legal background to support it. We started building 
this when we are almost ten years into awarding funds and that too was partially 
built on a trial and error basis by looking at the US system if it’s doable in Qatar to 
apply the same.” (Manager 5) 
 
When it comes to IRBs, four managers were adamant that the processes for IRB 
review and approval must be regulated and unified to avoid duplication, reduce 
burden and save time for actual research activities: 
35 
“One of the things that frustrate researchers in Qatar is that they have to apply to 
multiple IRBs if they want to have a collaborative research. One of the things I am 
proposing to the working groups is that we develop a reliance agreement for the 
whole country where then one IRB approval would cover all institutions.” (Manager 
1) 
 
“It is very challenging as every institution has their own guidelines, rules, 
paperwork, way of doing things and pathways for reporting.” (Manager 3) 
 
“I see some of the research institutions are placing a lot of barriers under the name 
of regulations and I really believe that IRB committees decisions and review 
process should be in place for two main purposes. First, for human subject’s 
protection and the second to help the PI’s by reducing the burden of regulations.” 
(Manager 4) 
 
“That created a lot of challenges to the investigators because after going through 
long phases of review and evaluation, most of them face difficulties with the IRB 
approvals.” (Manager 5) 
 
There were also regulatory issues specific to Qatar that were described by one of 
the managers regarding the legal system for criminal liability and the regulatory 
systems for clinical trial drug imports: 
“Another major barrier for undertaking clinical research in Qatar is the current legal 
setup where any person, if potentially harmed in a research study, can take criminal 
action against the study PI. This means that the PI would be immediately 
imprisoned until the investigation is completed and heavily fined if actually 
charged.” (Manager 1) 
 
“There are no clear regulations from the higher authorities about the import of these 
drugs for research purpose and basically the decision for import is taken on an ad-
hoc basis.” (Manager 1) 
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Table 1: Summary of the research barriers including themes and sub-themes 
according to managerials interviews.  
 Barriers: Themes Barriers: Sub-themes Examples 
1 
Professional/ 
Scientific 
Training 
 Research specific 
training 
 Monitoring  
Population 
 Absence of critical 
mass of researcers 
 Central support cores 
 Transient population 
 Retention of trained 
personnel 
Personal barriers for 
researchers 
 Clear pathways for 
clinician scientist 
 Protected time 
 Distinguish between 
roles 
 Recognition 
2 Administrative 
Processes 
 Administrative setbacks 
 Endless requirements 
 Too many steps 
involved causing delays 
Management 
 Lack of a focused 
strategic vision 
 Leadership stability 
 Communication  
Governance 
 Data access obstacles 
 Lack of institutional 
policies 
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 Inconsistency 
3 Financial Barriers 
Funding 
 Overspending and 
underspending 
 High cost compared to 
other systems 
Infrastructure 
 Core support facilities 
 Lack of research space 
 Optimum utilization of 
the available physical 
resources. 
4 Regulatory Barriers 
Legal framework 
 Most laws are either 
criminal or civil 
 Imported policies not 
suitable for Qatar 
Institutional Review 
Boards (IRBs) 
 Inconsistency in 
requirements 
 Too many IRBs given 
the limited number of 
institutions 
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Quantitative Study: 
Eighty-one proposals were awarded to HMC by QNRF from cycles 1 to 9 during the 
years 2007 until 2016 as the main awardee (Table 2), out of which 45 proposals 
(55.6%) are already completed and 26 proposals (32.1%) are still active. Out of the 
total, 26 (32.1%) projects were awarded directly to Lead PIs from HMC whereas the 
remaining projects had HMC PI as the Co-Lead PI. In all cases the main awardee is 
always HMC, however only the LPI has the access to submit progress reports to 
QNRF.  
Suspensions: The awarded projects received a total of 53 suspensions (including 
repeated suspensions for the same projects) with some projects being suspended 
for up to 4 times during their lifetime. The number of terminated projects for the 
same duration was nine (11%). On the other hand, there were 40 (48.7%) studies 
without any suspensions or terminations out of which 15 (37.5%) are still ongoing 
while the remaining 25 studies (62.5%) are successfully completed and closed.  
The most frequent reasons for suspensions were non-renewal of ethical approval 
(N: 23; 43.3%) followed by delay in submission of the progress reports to QNRF 
which occurred 16 times out of the total 53 times. 
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Table 2: Awarded proposals per cycle 
 
QNRF cycle No of projects 
NPRP 01 
NPRP 02 
NPRP 03 
NPRP 04 
NPRP 05 
NPRP 06 
NPRP 07 
NPRP 08 
NPRP 09 
5 (6.20%) 
3 (3.70%) 
8 (9.90%) 
14 (17.30%) 
15 (18.50%) 
10 (12.30%) 
19 (23.50%) 
4 (3.70%) 
4 (4.90%) 
Total 81 (100%) 
 
Other reasons included slow research project progress (4/53: 7.5%), deviation from 
the research protocol (2/53: 3.8%), transfer to HMC (2/53: 3.8), departure of LPI 
and change of LPI (3/53: 5.7%); LPI not reachable (1/53: 1.9%), administrative 
issues (2/53: 3.8%). There was also a mix of multiple reasons for suspensions as 
listed in table 3. Tabe 3 also identify whether the LPI was from inside Qatar or 
outside Qatar in each suspended project. When the reason of termination included 
a reason related to ethical issues, the LPI is most probably from inside Qatar, while 
when it is related to reporting delays and progress of the project the LPI is mostly 
from outside Qatar (Table 3). 
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Table 3: Reasons for suspensions 
 
Reasons of suspensions Number % 
LPI Inside 
Qatar 
LPI 
Outside 
Qatar 
No suspension 46 56.8 20 (43.5%) 26 (56.5%) 
Delay in progress report 
submission 
5 6.2 1 (20%) 4 (80%) 
Change of LPI affiliation 1 1.2 0 1 (100%) 
Slow progress 1 1.2 0 (0%) 1 (100%) 
Expiry of ethical approval 15 18.5 1 (100%) 0 (0%) 
Deviation in the study 1 1.2 0 (0%) 1 (100%) 
Ethical concerns 1 1.2 1 (100%) 0 (0%) 
Transfer to HMC 2 2.5 0 (0%) 2 (100%) 
Multiple reasons (Ethical expiry 
and Slow progress) 
1 1.2 0 (0%) 1 (100%) 
Multiple reasons (Delay in report 
submission and expiry of ethical 
approval) 
4 4.9 0 (0%) 4 (100%) 
Multiple reasons (Ethical 
concerns and change in PI) 
1 1.2 1 (100%) 0 (0%) 
Multiple reasons (delay in report, 
ethical expiry and administration 
issues) 
2 2.5 1 (50%) 1 (50%) 
Multiple reasons (ethical expiry 
and departure of LPI) 
1 1.2 1 (100%) 0 (0%) 
Total 81 100.0   
 
 
Suspensions are sometimes repeated for the same project in the same cycle as 
illustrated in figure 1.   
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Terminations: Nine projects out of the 81 were terminated (11.11%) for different 
reasons including disagreement between the PIs (N: 3; 33.3%), departure of LPI 
(old or second (N: 2; 22.2%) and other administrative issues (ethics, progress of the 
project or suspension requirements not addressed) (N: 4; 44.4%) (Table 4). Table 4 
also identifies whether the LPI was from inside Qatar or outside Qatar in each 
terminated project. When the reason of termination was related to administrative 
issues the LPI is most probably from inside Qatar while when it is related to 
disagreement between PIs or the content of the project it is amongst LPIs outside 
Qatar.  
 
 
 
 
 
 
 
0
5
10
15
20
25
NPRP 01 NPRP 02 NPRP 03 NPRP 04 NPRP 05 NPRP 06 NPRP 07 NPRP 08 NPRP 09
Figure 1: Trend of suspensions and terminations over different 
research cycles 
Awarded Projects Suspensions
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Table 4: Reasons for terminations 
 
Reasons for termination Number % 
LPI Inside 
Qatar 
LPI Outside 
Qatar 
Disagreement between PIs 3 33.3 0 (0%) 3 (100%) 
Departure of 2nd LPI 
without handover 
1 11.1 1 (100%) 0 (0%) 
Departure of old LPI 1 11.1 1 (100%) 0 (0%) 
Ethical concerns 1 11.1 1 (100%) 0 (0%) 
Administrative barriers 1 11.1 1 (100%) 0 (0%) 
Slow progress 1 11.1 0 (0%) 1 (100%) 
Suspension requirements 
not addressed 
1 11.1 0 (0%) 1 (100%) 
Total 9 100.0   
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Discussion 
 
This study investigated research barriers in Qatar using two methods, qualitative 
through interviews with research managers and quantitative by looking into existing 
research grants and investigating reasons for terminations and suspensions. Firstly, 
we will discuss these barriers from a managerial perspective and then from existing 
grants.  
 
Research barriers in Qatar from a managerial perspective: 
There were a number of barriers identified in the interviews, however many of them 
were not surprising as they are more or less similar to the barrier themes reported 
by researchers in other studies (Duley et al., 2008; Dilts & Sandler, 2006; 
Ehtesham et al., 2017; Ataee et al., 2015) but sometimes different in the actual 
content and suggested solutions. On mapping, they are condensed into 4 major 
categories or themes (Figure 2): 
 
Figure 2: Thematic presentation of identified barriers 
Clinical 
Research 
Professional/ 
Scientific 
Administrative 
Financial 
Regulatory 
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There were two major barriers that were common in all interviews – protected time 
and infrastructure. The research setup at HMC is unique wherein clinicians are 
contracted for clinical service and that is what their service contracts mainly focus 
on, however since the hospital’s focus for academic transformation; research is 
being considered for their promotions, annual appraisals, and budget requirements 
and so on. Even with all these efforts, not much has been done for securing 
protected time for clinicians interested in research. Almost all clinicians are 
undertaking research apart from their actual clinical duties, administrative and 
teaching duties. This poses the main barrier for conducting clinical research 
because it requires a lot of time and effort before, during and after execution of the 
research study. Lack of proper allocated time also affects the quality of the 
research because high quality research requires quality time for planning and 
implementing. However, managers have assured that this is being addressed at the 
highest levels to make it happen in the best possible way that would ensure 
continuity of the clinical service and allowing clinicians to undertake research for 
improving the quality of care provided to their patients.  
 
Infrastructure is another major barrier that was commonly identified by all 
managers, however each interpreted in a different way. Research space for clinical 
research appeared to be an immediate requirement since most studies suffered 
setbacks because of space. Issues related to appropriate rooms for consenting, 
equipment, research clinics and offices could all be traced to lack of appropriate 
space – mainly in the hospitals where the research occurs. There seemed to be a 
consensus among all managers in this regard as they received feedback from 
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researchers at their institutions about this issue quite a few times. Lack of space is 
also an issue when equipment is procured through research grants because 
although funding is available, there is no space to accommodate this equipment 
within the facility or they run into administrative barriers which are inter-related with 
the infrastructure issues. Another infrastructure that appears to be limited is human, 
in the form of clinical research support groups. Such groups include clinical 
research coordinators, research nurses, scientists, biostatisticians and technical 
writers. Research institutions usually invest in one or more core groups for research 
support which are utilized across more than one department within the 
organization. The funding is generated through the grants to sustain these core 
group while the institution also taps in some of the resources as and when required. 
These groups are missing in the research institution in Qatar. All research related 
tasks are carried by the same individuals who are also covering the clinical service 
and hence the quality of the research is compromised as the teams cannot work to 
their full potential in this case. One manager had a view that a modest investment 
in these groups would have a direct impact on the quality of the research and the 
expected outcomes from the ongoing research projects. Another issue that could 
be linked to infrastructure as well are the high cost for research compared to other 
systems around the world. The managers said this could be due to the fact that the 
research culture was still developing and any project included costs for other 
“indirect expenses” like for example when you hire a post-doctoral scholar, all his 
utility bills, rents etc. are inclusive in the budgeted salary which increases the salary 
to a very high rate. Other developed countries provide discounted residence for 
such temporary staff at a reduced rate and hence the salary is decreased 
significantly. The cost of living in the country is undoubtfully high too.  The recent 
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political embargo that the country is facing by the neighboring countries since June 
2017 has also had its effect on research expenses as now the materials, equipment 
and even travel has to be re-routed through other countries which adds to the 
actual cost significantly (BBC, 2019).  
 
The other barrier reported frequently in most interviews was the research 
mentoring and training. HMC clinician researchers were mostly educated and 
trained to be clinicians and not clinician scientists or clinical researchers. This could 
be attributed to the fact that good number of medical schools still follow the 
traditional teaching methods where you are taught to apply what you learn unlike 
the modern schools that depend mostly on research methods for teaching which 
build up the creativity and give them indirect training for clinical research after 
graduation. Hence most of the clinician researchers we have are self-motivated and 
self-educated when it comes to research. Again, since there is no protected time, 
there is only a certain level up to which they can get involved and apply what they 
learn. There are no identified pathways for identifying young clinicians with 
research enthusiasm and mentor them all the way from their early career until they 
are established researchers. Again, this does not require huge investment but only 
proper leadership that channels their enthusiasm into professional multidisciplinary 
career where they can excel as clinicians and researchers. However, these clinician 
scientists would also require protected time, startup funds and facilities to 
accommodate their research. Because of the transient nature of the country’s 
workforce, including clinicians, there are many senior clinician scientists who are 
hired at institutions in Qatar but they are not providing any mentoring or training to 
develop the local research community and eventually everything halts once they 
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leave the country and there is no human legacy to carry forward what they started. 
Hence it would be ideal to have compulsory training tasks assigned to the senior 
researchers to nurture local research scientists and share their experience to help 
develop a critical mass of clinician scientists in Qatar. 
 
Inconsistencies in IRB processes at different institutions and absence of a 
legal framework for research were also identified by most managers. The legal 
framework includes policies and procedures that govern research, outcomes, 
Intellectual Properties, import of clinical trial drugs or devices and financial 
indemnity. One of the major issues related to legal framework was that there was 
no law governing clinical research in Qatar as of now, though many drafts were 
reviewed by institutions over different time periods, but none came into existence. 
The current draft was not very positive either, according to one of the managers. If 
applied, the law would mean that any research participant claiming to be harmed in 
a research project, would then be able to complain against the LPI under the 
criminal law which means immediate imprisonment of the PI until all investigations 
are completed to prove or deny any misconduct. The application of such a law 
would put an end to the clinical research in Qatar because the researchers would 
feel unsecure about anything that could go wrong because it might ruin their career, 
even if they proved innocent eventually. Researchers had also relayed their 
frustrations to the managers about the difficulty in obtaining IRB approvals for 
clinical research because of the inconsistencies in the requirements and processes 
at each institution and hence having collaborative projects was becoming 
challenging rather than encouraging with the current systems. 
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One of the interesting findings in this study was that few managers felt that there 
was a “gap” in the expected outcomes from the current investment and the current 
reality. They said that although the investment is significant, the absence of 
conducive systems at all levels was a main barrier to achieve what the State 
(government) and the community expected. They also said that the timelines were 
unrealistic too compared to the effort required to build these systems and start 
working through them.  
 
However, the managers did confirm that this “gap” and all other barriers identified in 
their interviews was not something unheard of and the higher officials were aware 
of the issues since these were discussed in many of the high-level meetings that 
they attend. There were solutions being implemented to address all these barriers 
in an effective and strategic manner. 
 
Research barriers in Qatar from existing grants (observational retrospective 
study): 
Discussing the quantitative study, HMC has received a large number of grants 
through QNRF’s flagship funding program – the NPRP. However, the management 
of these proposals apparently was not very easy and went through many hiccups. 
The number of suspensions is relatively high compared to the number of awarded 
grants at the average of 0.65 per proposal which hints that proposals are more 
likely to face a suspension during their lifetime for one reason or the other. The 
number of proposals in the endangered zone is slightly higher than the ones in the 
safe zone but not a significant difference. It goes without saying that a research 
office for a reputed institution like HMC must maintain a far better record than the 
49 
current to reflect a better image to other stakeholders and the funding agency as 
well. 
 
A closer look into the numbers reveals a trend of suspensions and terminations 
over different cycles as illustrated in figure 1. The number of suspensions started 
increasing in cycle 3 and peaked at cycle 5 where it exceeds the number of 
awarded projects. This means that the same proposal would receive multiple 
suspensions.   
 
However, coming to the reasons behind the increase in suspensions, this was a 
transition stage for QNRF as a funding agency and HMC as a research office. As 
for QNRF, they gained further experience from the first 3 cycles and hence decided 
to transform the way grants are managed by launching their online grant 
management system – Qgrants. Until then, all progress reports and other 
requirements were communicated through emails and even hard copies sent to 
QNRF offices. With the launch of the system, there was a confusion about the 
tracking of the reports as some LPIs continued sending offline reports and denying 
to accept the fact that submissions were online now. As such, QNRF would not 
hesitate to issue suspensions for any project with a delayed report. The system is 
electronically timed and hence any report that misses the deadline raises a red flag 
at the award administration team and they would prompt a suspension notice 
immediately. However, the system was not much user friendly at all times and had 
its own cons that QNRF would consistently work on improving them. As for the 
transition at HMC research office, there were many changes in the research office 
personnel and turnovers that would often make it difficult to keep track of the grants 
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progress. The focal point of contact, AROR, had changed around 3 times in these 3 
years without a proper handover to the successor. Absence of an electronic 
monitoring tool at the research office added up to these problems as manual 
tracking for bulk of these projects in a timely manner was challenging for a single 
person to handle.  
 
Results also showed that the most frequent reasons for suspension were non-
renewal or delayed renewal of ethics approval and delays in progress report 
submission. As for the delays in progress reports, part of the problem has been 
explained in the above paragraph. The other main factor that contributed to these 
delays was the Lead PIs that were external to HMC and Qatar. To enable RCB in 
Qatar through collaborations with established researchers abroad, QNRF allowed 
Lead PIs from outside Qatar to submit proposals to obtain funding through its 
programs, however there was a condition to have a Co-Lead PI from an institution 
within Qatar. The problem was that the access to progress reports and other 
communications was solely granted to the Lead PI without any role for the Co-Lead 
PI in the process. Hence in case of delays or approaching deadlines, it would 
become extremely difficult to reach out to the external Lead PIs as the only method 
would be emails. This was not very effective as the research office would be under 
the risk of suspension or even losing the grant if the Lead PI would not be 
reachable in this case. Many of these suspensions would have been avoided 
should the Co-Lead PI would have access to the same channel as contacting the 
local PI is much easier and effective. The issue was raised with QNRF in many 
meetings until they finally changed their rules to prohibit any Lead PI from outside 
Qatar to submit a project under their name. However, they were still allowed to 
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collaborate with Lead PIs submitting from the institutions based in Qatar. 
Unfortunately these changes were applied only from cycle 9 onwards, however a 
quick look at Figure 1 shows zero suspensions in that cycle where the projects are 
already in their final year. On the other hand, looking at other reasons for 
suspensions, we can see that there are no differences between LPIs inside or 
outside Qatar especially when the reasons are related to institutional issues such 
as ethical approvals.  
 
Coming to the ethics approval, we have to start first by highlighting the fact that 
research – or clinical research specifically – is a relatively new concept in Qatar and 
the region compared to advanced research systems in Asia, Europe and the 
Americas. Hence the clinical research governance has been through 
transformations to find the ideal framework for the Qatari research system. 
However, everything comes with a cost and hence the cost of these 
transformations was changes in the IRB review and administration system in more 
than one institution across Qatar. The Ministry of Public Health guidelines for 
clinical research were also published not long ago. At HMC, the ethics committee 
was a small committee that would meet on a weekly basis and decide on the 
proposals being submitted by HMC researchers. Since the funding was very 
restricted, the volume and the nature of submitted studies would be at that level too 
hence the need for sub-specialty reviews or external opinion was very rare. 
However, with the changes in the research policies and the increased funds for 
research, the need for an advanced ethics review became evident. Hence HMC 
decided to partner up with Weill Cornell Medicine Qatar (WCMQ) to establish a joint 
ethics board where HMC would benefit from WCMQ’s expertise and vice versa. 
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The joint ethics board was administratively managed by representatives from both 
institutions. The committee did start off well but unfortunately could not keep up 
with the load of proposals being submitted for review. At one point, the waiting time 
for an initial review of a proposal by the committee reached to more than 3 months. 
There were also other issues with the electronic submission system used for the 
ethics review and the majority of the researchers in both institutions were not happy 
about it. Hence these delays are reflected in the number of suspensions as some 
studies would be pending review at the committee and the PI being helpless about 
it. Eventually the joint ethics board was dismantled and a new Institutional Review 
Board (IRB) was set up for HMC alone. This was a relief for researchers at HMC 
but again came at its own cost because the new IRB decided to suspend all studies 
until these were resubmitted per the new guidelines for review and approval. This 
added up further to the suspensions received at that time period. However this 
issue is now resolved and the improvement can be noticed from cycle 7 onward. 
 
Terminations were not very frequent for HMC grants. Only nine grants were 
terminated and looking further into the reasons for termination, there was nothing 
unusual. In most cases, termination was invoked due to departure of the LPI from 
the awardee institution. QNRF rules allow handover of the project to qualified 
researchers within the same institution, however where the original Lead PI decides 
to leave the institution due to disputes with the administration, unfortunately they 
use the grant as a “revenge” and decide not to sign on the handover documents. 
QNRF requires that the handover must be signed by the original Lead PI. 
Eventually the grant is terminated. There was also one incident where there was a 
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disagreement between the Lead PI and the Co-Lead PI and HMC had to initiate the 
termination in this case.  
 
If we compare the outcomes of the qualitative and quantitative studies, the issues 
identified in the quantitative fit within the themes of the barriers. For example, lack 
of appropriate management systems falls under administrative barriers, shortage in 
personnel under financial barriers and absence of IRB approvals is due to the 
complications in the IRB systems which is a regulatory barrier. Even for cases 
where terminations were due to non-response or disagreement between PIs, it falls 
under professional barriers because if the researcher was aware of his roles and 
responsibilities as a Lead PI, they would adopt a constructive approach to resolve 
matters rather than choosing the hard way that has negative consequences. 
 
Future Implications: 
The topic of this study is of great interest at a time where no previous study has 
explored these barriers, especially in the state of Qatar. The outcomes of this study 
will be disseminated through publication and relevant conferences and 
symposiums. The results will also be communicated separately to the higher 
authorities involved in decision making for research related matters. The results of 
the study will help policy makers and research authorities and institutions to look 
into solutions to overcome these barriers. The study has clarified the overall 
research barriers as well as specific ones (through themes and sub-themes, see 
table 1) and thus will help policy makers and research institutions to rectify these 
barriers by looking at specific examples and real world data results directly from 
research managers who mostly have clinical and administrative experience.  
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Nevertheless, one of the most important outcomes of this study is that it will lay a 
strong foundation for the next phase of the study that involves exploring the barriers 
from the researchers’ perspective and analyse these perspectives for any gaps to 
be addressed or efforts to be streamlined for both – researchers and managers. 
The policy makers will then have a full picture about the research ecosystem in 
Qatar. 
Conclusion 
This research study had several positive outcomes. We were successful in 
identifying the barriers to implementation of clinical research. Categorizing these 
barriers into the themes described in the results and discussion section will help to 
focus on those areas to tackle these barriers and streamline the processes at all 
levels. The study also identified other barriers that are unique to the Qatari research 
environment. The outcomes could be generalized to clinical research setting in 
other counterparts in the Arab world where the research environment is more or 
less the same as Qatar. 
 
To the best of our knowledge, this study is the first in the world that addresses the 
managerial perspective of the barriers to conduct of clinical research. It also paves 
the way for future research in this field. The results will be communicated to the 
policy makers in the Qatari Research Leadership to provide them with real-time 
feedback of the current situation thereby helping them direct their efforts to prioritize 
tackling these issues in an efficient manner. It is evident from the interviews that the 
leadership is already aware of these barriers and massive efforts are being directed 
towards addressing these issues at the highest level. 
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Limitation 
One of the limitations of the study is that it focuses on the research managers and 
executives perspectives’ only, hence the generated data is limited but of high 
quality. However, we also included data from existing grants where we looked at 
ongoing research from different perspectives. Also, the current study lays a strong 
foundation for pursuing further research that could include the researchers in the 
clinical research environment in Qatar.  
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Appendix 1 
 
 
PARTICIPANT INFORMATION SHEET 
 
Dear Participant, 
 
You are invited to participate in Project title: 
 
“Barriers to Implementation of Clinical Research in Qatar: A Managerial Perspective” 
 
 Name of Principal Investigator: Saad Al Tamimi, Hamad Medical Corporation  
 
This research study is being conducted among the research managers in Qatar to identify 
the barriers to implementing clinical research in Qatar from the research managers’ 
perspective. Clinical research is generously funded however it is important to know if the 
current systems are supportive enough for these funds to be utilized in an optimum 
manner. The study will include research managers of the key stakeholders in the clinical 
research community in State of Qatar. 
 
The research has received a favourable ethical opinion from the Research Ethics 
Committee of the Faculty of Business and Social Sciences at Kingston University London. 
The study has also been approved by the IRB at HMC. 
 
You are invited to take part in a face to face interview. The interview will be audio-
recorded for transcription purpose. You will be asked questions about the clinical research 
environment in Qatar, strengths and weaknesses, barriers to successful implementation 
and proposed solutions. 
 
Your participation in this research is completely voluntary. You can stop the interview at 
any time or choose not to answer any question. 
 
The interview is expected to take 30-45 minutes of your time and no further interaction 
will be required after the interview. 
 
There are no direct benefits to you by taking part in the research. However, I believe that 
your experience with the research environment in Qatar will be of great value to this 
research study. Identifying and categorizing these barriers will help to focus efforts on 
those areas and streamline the processes at all levels. The study might also identify other 
barriers that are unique to the Qatari research environment.  
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There is no risk to participate in this study. The interviews will be confidential, and the 
transcriptions will be anonymized. The audio-recordings will be destroyed once the 
transcription is completed and verified. 
 
You have the right of knowing the results of this study at the end of it. 
 
If you have questions or concerns, or if you think the research has hurt you, talk to the 
research team: Saad Al Tamimi, Tel: 55909086 and sabdullah5@hamad.qa or Prof 
Muthanna Samara at M.Samara@kingston.ac.uk  
 
 
If you have questions about your rights as a volunteer, or you want to talk to someone 
outside the research team, please contact: 
 HMC research office at Tel: 44392440 or research@hamad.qa 
 
If you wish to complain about any aspect of how you have been treated in this research, 
please contact Professor Jill Schofield who is the Dean of the Faculty of Business and Social 
Sciences at Kingston University London. Professor Schofield's contact details are as follows: 
Dean's Office, Faculty of Business and Social Sciences 
Kingston University London, Penrhyn Road, Kingston upon Thames KT1 2EE. 
Email: j.schofield@kingston.ac.uk 
Tel: 020 8417 9000 ext. 65229'. 
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Appendix 2 
Informed Consent for “Barriers to Implementation of Clinical Research in Qatar: A Managerial 
Perspective” 
Please tick the appropriate boxes Yes No 
 
1. Taking part in the study 
I have read and understood the study information dated [30/Jan/2019], or it has been read to 
me. I have been able to ask questions about the study and my questions have been answered to 
my satisfaction. 
  
  
I consent voluntarily to be a participant in this study and understand that I can refuse to answer 
questions and I can withdraw from the study at any time, without having to give a reason.  
  
 
 
I understand that taking part in the study involves a face to face interview about the clinical 
research environment in Qatar that will be audio-recorded for transcription purpose. The 
recording will be destroyed once the transcription is completed and verified. 
 
 
 
 
 
 
2. Use of the information in the study 
I understand that information I provide will be used for the thesis of the PI’s degree and could 
be published later however the publication will not include any identifiers or information that 
could disclose my identity. 
  
 
I understand that personal information collected about me that can identify me, such as my 
name or where I live, will not be shared beyond the study team.  
 
 
 
 
 
 
 
I agree that my information can be quoted in research outputs.   
 
3. Signatures 
 
_______________________                              ____________________                ___________ 
Name of participant [IN CAPITALS]      Signature                                Date 
 
I have accurately read out the information sheet to the potential participant and, to the best of 
my ability, ensured that the participant understands to what they are freely consenting. 
 
_______________________                        ___________________      _    ________               __    
Name of researcher [IN CAPITALS]      Signature                                  Date 
 
4. Study contact details for further information  
 Saad Al Tamimi, Tel: 55909086 and sabdullah5@hamad.qa 
 Prof Muthanna Samara at M.Samara@kingston.ac.uk 
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Appendix 3 
Invitation Email 
 
Dear Participant, 
 
I am a Master’s student at Kingston University London and I am conducting a research 
study titled “Barriers to Implementation of Clinical Research in Qatar: A Managerial 
Perspective”. The study will include research managers of the key stakeholders in the 
clinical research community in the State of Qatar. 
 
As part of this study, I am seeking to conduct interviews with research managers and 
executives in the clinical research community in Qatar. I am approaching you because of 
your experience as a research manager/ executive for past years in funding/ managing 
clinical research in Qatar. This research study has received a favorable ethical opinion from 
the Ethics Committee of the Faculty of Business and Social Sciences at Kingston University 
London and Medical Research Center - HMC. 
 
Together with your help I hope to gather insights into how these barriers could be 
identified and tackled. Your experience and understanding of these issues would make an 
invaluable contribution.  
 
You will be asked questions about the clinical research environment in Qatar, strengths 
and weaknesses, barriers to successful implementation and proposed solutions. 
The individual interviews will take place in person and are expected to take approximately 
30-45 minutes. Please read the attached Participant Information Sheet and let me know if 
you are willing to participate by replying to this email. 
 
In case you agree to participate in this study, please provide a suitable time and location 
for this interview at your convenience. 
 
Please let me know if you have any further queries about this research study. I will be glad 
to address any concerns in this regard. 
 
I look forward to receiving your positive response. 
 
Regards 
 
Saad 
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Appendix 4 
Semi structured interview guide 
1) Educational background:   
a. Clinical 
b. Administrative 
c. Both 
2) Age:  
a. 40-50 
b. 50-60 
c. Above 60 
3) Could you tell me about your role as a ______________? 
4) What is your experience with clinical research/ management?  
a. How many years?  
b. What aspects?  
5) How would you describe the support provided by the State of Qatar for clinical research? 
6) What about the support within your institution and its contribution in this regard? (programs, 
protected time, training) 
7) Do you believe that the funding allocated for clinical research is being used effectively? How is 
this captured/ monitored? 
8) Does your institution provide dedicated facilities for research? (labs, offices, storage) 
9) What do you think motivates or demotivates researchers within your institution? 
10) How would you describe the overall attitude of the clinical researchers within your 
organization? 
11) How frequent are research related issues discussed or policies revised within your institution? 
12) Do you think that there are any barriers specific to your organization?  
a. For each barrier mentioned can you explain whether there are any steps taken to try 
and solve it?  
b. If yes, what are the steps? 
i. Was it successful?  
ii. If not, why?  
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c. If no, why?   
13) Do you think that there are any barriers specific to the State of Qatar only? 
14) Are there any other barriers that we didn’t discuss in this interview that you would like to add? 
15) What is in your view would be the solution to overcome these barriers? 
a. Barrier 1: 
b. Barrier 2: 
c. Barrier 3: 
d. Barrier 4: 
e. Barrier 5: 
f. Barrier 6: 
g. Barrier 7: 
h. Barrier 8: 
i. Barrier 9: 
j. Barrier 10: 
  
66 
Appendix 5 
 
  
 
 
 
 
 
 
 
 
19 February 2019 
 
Mr Saad Mohammed Abdullah Shahbal 
MSc Student 
Department of Psychology 
School of Psychology, Criminology and Sociology 
Faculty of Business and Social Sciences 
Kingston University 
 
 
 
Dear Saad 
 
Barriers to Implementation of Clinical Research in Qatar: A Managerial 
Perspective 
 
To confirm that you ethics application 1819CHA1 entitled: ‘Barriers to 
Implementation of Clinical Research in Qatar: A Managerial Perspective’ received a 
favourable opinion from the Deputy Chair on behalf of the Faculty of Business and 
Social Sciences Research Ethics Committee on 14 February 2019.  
 
Yours sincerely 
 
 
Emma Finch 
Research Operations Manager  
Clerk of the Faculty Research Ethics Committee 
Faculty of Business and Social Sciences 
Kingston University 
  
Faculty of Business and Social Sciences 
T  +44 (0)20 8417 9000  Penrhyn Road 
F  +44 (0)20 8417 2292  Kingston upon Thames 
www.kingston.ac.uk   KT1 2EE, UK 
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Appendix 6 
 
Barriers to Implementation of Clinical Research in Qatar: A Managerial 
Perspective 
 
Participant Debrief Sheet 
 
Thank you for participating in the face to face interview. The information you provided is 
very valuable for the purpose of our research and we are grateful for your contribution. We 
hope that you have found it interesting and have not been upset by any of the topics 
discussed. 
 
However, if you have found any part of this experience to be distressing and you wish to 
speak to one of the researchers, please contact:  
 Saad Al Tamimi, Tel: 55909086 and sabdullah5@hamad.qa 
 Prof Muthanna Samara at M.Samara@kingston.ac.uk 
 
If you have questions about your rights as a volunteer, or you want to talk to someone 
outside the research team, please contact: 
 HMC research office at Tel 44392440 or email: research@hamad.qa  
 
If you wish to complain about any aspect of how you have been treated in this research, 
please contact Professor Jill Schofield who is the Dean of the Faculty of Business and 
Social Sciences at Kingston University London. Professor Schofield's contact details are as  
follows: 
 
Dean's Office, Faculty of Business and Social Sciences 
 
Kingston University London, Penrhyn Road, Kingston upon Thames KT1 2EE. 
 
Email: j.schofield@kingston.ac.uk 
Tel: 020 8417 9000 ext. 65229 
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Appendix 7 
Manager 1 
** The interviewee is welcomed to the interview and briefed about the study ** 
 
Educational Background: Both 
 
Age: Above 60 
 
Saad:  
Could you please tell me about your role as an Institutional Research officer at your 
institution? 
 
Manager 1: 
My role has a number of components. As Institutional Research officer, I am responsible 
for research governance across my institution. In practical terms, it means I have the 
executive responsibility of the Medical Research Center (MRC) and its activities. The 
second half of my role is the Executive role at the Academic Health System (AHS) and 
program development. We are bringing partners across Qatar into a unified academic 
health system.  
 
Saad: 
Could you elaborate more on your experience in management of research? 
 
Manager 1: 
I have been a clinical scientist myself. I began research in 1987 and finished my high degree 
in 1991. Since then I have been a clinician scientist. I have been Prof of Medicine and held 
2 chairs through British Health Foundation. The chair position comes with acute 
administrative responsibilities. I was also the Dean of Medical School. These roles had 
activities related to research administration and governance. 
 
Saad: 
You have been in Qatar for almost 9 months now so how would you describe the support 
for clinical research in Qatar? 
 
Manager 1: 
It is indeed an evolving culture and there is huge encouragement for research. Through the 
funding available by the MRC, support is being provided through grants, training and 
infrastructure. The state is also providing funding indirectly through other channels and 
some oversight through the Ministry.  
 
There are issues in terms of doing clinical research that we have to overcome before we 
are a mature research system. The first is, from the point of quality of research being done, 
there is huge enthusiasm for research but I think we are yet to have a proper critical mass 
of really experienced researchers. That is important if we want to achieve good quality 
research. Part of this is achieved by bringing together parties across Qatar so we can 
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strengthen basic science input to increase the level of clinical interaction. The issue here is 
not only the creation of this mass of researchers but also planning for the legacy that 
benefits our institution. It wouldn’t be effective again if we bring in researchers from 
abroad who would then initiate and publish research and then everything is over the 
moment they leave our institution. Hence, we should ensure that the local talent is built 
within this culture through training and mentoring such that the process continues all 
along. There should also be a clear pathway for identifying the young clinicians with 
interest in research such that they are guided from their final stages of medical school and 
mentored and trained as researchers and when they return here, they are given 
appropriate time allocation for research and clinical commitments. They must also be 
given proper access to the research facilities across Qatar. This also brings us to the issue 
of lack of protected time for researchers because it is a real problem where the clinicians 
are expected to provide research output and spend time conducting research but at the 
same time expected not to compromise their clinical duties, which is of course their main 
duty as clinicians here.  
 
I have suggested to the higher management that we must seriously consider having a 
national research data registry that could provide real and reliable data to the researchers 
in Qatar and collaborators who wish to implement studies here. The problem currently is 
that we don’t have reliable statistics about the patient population or the clinical burden of 
different diseases in Qatar and this is critical. The task is huge but if we are allowed to use 
the budget we have for the current year, I believe this is doable and if done as planned, it 
will be like a national treasure for researchers and Ministry for planning. 
 
Another important barrier is the research governance and by governance I don’t mean the 
policies as such because the policies are very well drafted but then the personnel allocated 
to ensure proper implementation of these policies and guidelines is just not sufficient. We 
don’t have enough hospital research officers or clinical monitors for having the site 
initiation visits or monitoring of ongoing research projects. We need to be pro-active in 
avoiding compliance issues but the available research personnel only allow us to be 
reactive to a certain limit.  
 
Lack of personnel is again an issue if we are aiming to implement clinical trials because the 
available staff and expertise is good enough to support the clinical service but not research 
trials. We need trained research support staff like nurses, technicians, trial coordinators 
etc. to support clinical trials. I believe that we are one step far away from this and all we 
need is a modest investment to increase our human capital and we can overcome these 
issues.  
 
We also have issues for research space to accommodate the different research trials 
happening across our institution. The Translational Research Institute (TRI) would solve all 
these space issues but that won’t happen until the next 5 years or so. In the meantime, we 
requested extra floors in the Medical City and expecting to receive this space soon. 
 
There are barriers in the regulatory system for trials involving new drugs and devices. This 
sometimes delays import or is discouraging for sponsors to implement trials in this setting. 
70 
Personally, I don’t think that the load of the trials we receive is large enough to call for 
revising the regulations but instead I suggested that we use the support from external 
bodies like Medicine Health and Research Agency (MHRA) at the UK. The MHRA would 
then be responsible to train the relevant personnel at Qatar and also review the import 
requests that we receive and provide approvals accordingly. This would be more feasible 
cost and effort-wise. 
Financial indemnity for research is another barrier that I believe has to be highlighted here. 
So far, this wasn’t seen a priority in the research setting here but since the insurance 
scheme is going to be applied soon, this barrier has to be looked into seriously. Research 
costs cannot be factored into the service costs. There are no clear-cut policies in the 
costing as well as we notice that the judgement is based on personal relations or individual 
relations rather than dependent on policies that would apply equally to all research 
studies. Hence there is an immediate need for it. 
Another major barrier for undertaking clinical research in Qatar is the current legal setup 
where any person, if potentially harmed in a research study, can take criminal action 
against the study PI. This means that the PI would be immediately imprisoned until the 
investigation is completed and heavily fined if actually charged. This shouldn’t be the case 
unless if real case of deliberate harm by the PI is proved. The public would usually take the 
criminal route because the course of action is much quicker than the civil route. This poses 
a great threat to the PI because any case of potential harm or adverse event in a research 
study could end their career as a physician and hence the stakes are very high here.  
 
These are the most important barriers the way I see them in the Qatari system. 
 
Saad: 
Thank you for listing the barriers. If we talk about the funding, it is generously funded but 
then do you think that the allocated funds are fully utilized for research or there are other 
factors that hold funding or “sieve-off” the funding at different levels? 
 
Manager 1: 
Yes of course there are barriers. One of the main issues that we face for funding in general 
is being underspent but then this has other reasons. For example, if we budget for a 
clinical trial but then the team is not able to recruit the required personnel due to the 
stringent procedures, the outcome is underspending but this does not reflect the true 
picture because the underspending was due to these barriers. The financial status in the 
country is now more stringent and hence any investment needs outcomes to justify it to 
the management. As I mentioned, the costs of the lab tests and other research procedures 
are not controlled through clearly defined policies but depend on personal judgements. 
This needs to be addressed sooner than later to measure the actual costs of research and 
charging them against the relevant accounts. 
 
Also, there is the issue of indirect cost (IDC) that needs to be addressed by our institution 
on how this has to be allocated or utilized. In UK for example, the indirect cost is used to 
cover the actual costs for the additional research tests and procedures and hence they 
charge indirect costs for these grants. These research costs are also covered through a 
central account that is fed in through the central government and then the universities 
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recuperate into this account. This is necessary in that system because for the universities 
teaching makes money and research loses so they have to compensate. However, I don’t 
see how this could be applied in the system in Qatar and hence there should be better 
ways to manage the IDC to be used more effectively. 
 
Saad: 
How would you describe the overall attitude of the clinicians at our institution towards 
research? 
 
Manager 1: 
I would say that there is great interest in doing research but then the practically of it is not 
possible. There is no protected time for the researchers and if we are looking for top 
quality research, then it’s not something that could be done a couple of hours after duty. I 
think there is a strong case to identify good researchers and give them protected time to 
be able to do research because the issue is that we either pay them additional amounts for 
undertaking research or provide them protected time. On the other hand, QNRF’s view is 
that they are paying for the time but not the salary of the researchers and I understand 
their argument too. The prevalent view among researchers is that if you are not going to 
pay me or give me protected time then why would they do research.  
 
Saad: 
What do you think motivates or demotivates clinical researchers at our institution? 
 
Manager 1: 
The motivation is that it adds variety to their job because in the end we are all trained to 
be clinicians. Being 10 to 15 years in the job as a consultant, apart from the joy of helping 
people of course, there is a routine in the daily work we do. Hence research adds variety to 
the job which in turn increases job satisfaction I believe. For many other, publishing and 
presenting their researchers adds prestige to their identity. Hence for the substantial 
minority undertaking research here, I would say that there is high enthusiasm but also 
some sort of unhappiness that it is unrecognized by the institution in terms of protected 
time or salary.  
 
Saad: 
So, these are the things that would demotivate them? 
 
Manager 1: 
I think for some of them but for some other it doesn’t. There are some people who are so 
driven that they will do research in the little time they have no matter how busy they are. 
 
Saad: 
Coming to the policies, how do you think your institution’s policy framework supports 
clinical research? 
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Manager 1: 
I think AHS-MRC have pretty well-defined policies that stand up to scrutiny but I think the 
strategy of developing it could be improved. As far as we are concerned, I think - though 
not deliberate – there is a disconnection between the reality and what is expected. If we 
are willing to say that we are a world class academic health system undertaking research, 
when it comes to the crunch in difficult times, from the clinical service, research is 
inevitable taken as a back burner. I don’t say that in a critical way though. So, if we say it 
this way then research will always take the second place because there is always a clinical 
issue that would be a priority. Yet we know by looking at other organizations that do 
prioritize research that they get better clinical outcomes. So, it’s a case of short-term 
challenges against the long-term impact of having an academic health system and how you 
change that balance. Qatar could do better than compared to other places because in 
places where there are regular elections, programs are encouraged for short terms but 
then the political system here is more stable and can plan for the long term. I personally 
believe that it’s time for doing that now because I understand why the academic agenda 
stalled around in 2015 due to the financial cuts but then it can’t be cut off forever. At the 
moment, and I’m not being critical, but I understand that there is more rhetoric than 
reality. The government here is not working on a research strategy and we are currently 
feeding into the health aspects of it. I would like to see a central funding for the AHS 
because at the moment our institution bears all the costs and hence it is seen as an 
internal matter and not national. There could be a 5-year plan to transform ourselves into 
an academic health system with research at its core but this needs a lot of work that the 
higher management and senior clinicians fail to see this gap. For politicians, maybe we 
have not done a good job proving to them what an academic system could do to help with 
improving the system and hence we needed to show value for money invested. In 
business, it makes sense that the growth 5 years from now would depend on the value for 
money invested and the same is true for health. We have to demonstrate that we have 
robust systems in place to show them how the money is spent. 
 
Long answer to your question, I think more centrally there is more skepticism about 
importance of research in most sections of the corporation and externally and among 
politicians. Although they like to use the rhetoric on websites, I am not sure they are fully 
committed and we have a job to make sure that they are committed. 
 
Saad: 
If we take the business mentality of the politicians, then they would argue that they 
allotted a certain sum of money when in crisis and we managed fine with it so why would 
they have to increase now? We would need strong justifications for that. 
 
Manager 1: 
Yes, I wouldn’t disagree with this. The other issue that we should be able to prove that we 
are effectively spending what we receive. For example, if we fully spent this year’s budget 
on a national data capture system, we would be able to show the legacy we created from 
this expenditure. I believe that this national system will not only serve the researchers but 
also for informing health policy going forward. Once we start doing these things, people 
will start getting convinced that money is being well spent. My understanding when I came 
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here was that this never happened before and all it mattered was that the allocated 
funding was being spent in a “good way”. Probably it wasn’t asked earlier because money 
was easier back then but its tighter now and we have moved to a new era where we have 
to compete with other agendas. In a way, we have to also be ready for a time where the 
higher management could change so we must have this data to convince anyone who 
would take over then.  
 
Saad: 
Do you think that the policies and guidelines at your institution would motivate or 
demotivate clinical researchers? 
 
Manager 1: 
I think they are complex and none of the researchers know all the policies inside out – we 
are not expecting that from them. That’s why the hospital research officers and clinical 
monitors are important because we need people in the ground who can educate the 
clinicians and ensure that the policies are instituted. The sentiment of the policies is very 
crucial and we have to make sure that if they want to do research then they go by it but we 
can’t hold them totally accountable. My slight worry here is the research law that the 
Ministry is proposing and that is why I was trying to hold it down because it removes 
institutional responsibility and holds the investigator responsible. In that case, majority of 
ongoing research would stop with negative consequences. Ultimately our job becomes to 
train and support clinical researchers to ensure that they are compliant with the rules and 
regulations and if someone breaches them then clearly it has to be addressed. The issue 
remains though if the breach was done in good faith or if someone systematically and 
deliberately breached patient safety and if they have then they should face the 
consequences. However, for a one-off case where it was done in good faith, then we 
would have done our part in avoiding all that.  
 
Saad: 
The barriers that you listed earlier in the interview, are they specific to your institution? 
 
Manager 1: 
I would say across Qatar. I think many of the same would apply but the research done in 
Primary Health Care is relatively low risk but then Sidra would have similar issues to ours. 
The issues become more severe with higher risks involved. 
 
Saad: 
Are the barriers specific to Qatar? Or would you say it’s similar to other systems you have 
worked in previously? 
 
Manager 1: 
I don’t think all of them because some of them are different. For example, UK is very 
bureaucratic country and very rigid when it comes to applying rules. If you combine a rule 
applying mentality with thousands of rules to be applied, you end up with inertia to 
progress. Part of the problem for UK is that European Union believes in lot of rules and 
churns out thousands of rules every year. Large parts of the EU however treat these rules 
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in the manner how they should be, as a guidance rather than rules. The UK however 
embraces them and there is an army of people to apply these but if you read them, 
nothing actually would happen if you apply them. This is not specific to health only but all 
other sectors like business, communication etc. So, we (in Qatar) are not unique. I got a 
grant from the National funding body during my time in Aberdeen but then I moved to 
Norwich by the time it was awarded. It took me 3 years to move these approvals and the 
grant from Aberdeen to Norwich. The grant was finished by the time we got the approvals 
and we had to request a no-cost extension which was only for a fraction of the actual 
duration and the science was old too. So many of these problems here (in Qatar) are not 
unique. Investigators think it’s terrible and so we have to resolve it but it’s not unique. I 
would say that what other countries have had is much longer time to put sophisticated 
systems in place because they have been here longer so I see that we should take the best 
of these systems and adapt them to our needs here, like the regulatory structures for 
drugs. Qatar’s development in this field is very recent maybe around 30 years so it’s not 
possible to move from one stage to another very quickly as some would expect. 
 
Saad: 
Lets go back to the barriers you identified in this interview. I will name them and perhaps 
you could let me know what is being done or already done to overcome that barrier. 
Barrier Steps taken to solve 
Critical mass of clinical researchers I think we made a little progress through the 
clinical institutes but then the numbers are 
still small. I did a search of H-index of 
researchers around our institution and if we 
consider that an H-index of 30 would take 
you roughly to the international level, we 
have got only 5. We lack the strong mass of 
researchers across our institution to mentor 
the really enthusiastic people. I think we 
need at least 20 and if we look at the 
number of consultants that we employ 
every year we can surely do that. But then 
legacy is important because we can’t have 
them for 3-4 years and then leave without 
any forward plan.  
Mentoring and Training Part of their role has to be mentoring and 
the other part of mentoring is not only 
developing the current senior people but 
also creating a pathway for clinician 
scientist. This involves Medical education, 
ourselves and other partners. One of the 
things I am waiting for is appointing my 
deputy and part of their responsibility that 
they will take on is the legacy issue. We are 
working to create a pathway for the Qataris 
to become clinician scientists in future. 
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Protected Time I’ve raised it with the higher management 
who are sympathetic. I also have an 
upcoming presentation later this year and I 
will raise it again. The proposed solution 
would be that we agree a percentage FTE 
across the institution that would be devoted 
for protected research time. Then we would 
ask executives of the facilities to identify 
individuals based on the quality and 
quantity of research who would benefit 
from this. It should be for people who are or 
have the potential to be serious researchers.  
Governance issues I have fought very hard to have the HROs 
and monitors. I had meetings with HR and 
expect later this week to have more posts 
approved for MRC. 
Policies They would be tweaked and refined but I 
don’t think we can simply further because 
there will always be a mismatch between 
what JCI would expect and a clinician would 
prefer. So, in order to meet JCI 
requirements they have to be detailed but 
then our job is to make life easier for the 
researchers. 
Facilities and infrastructure We are in the middle of preparing a bid for a 
clinical research facility. This would be for 2 
floors at one of the buildings at the medical 
city. 
Modest Investment in personnel One of the issues is the mismatch between 
operational, capital and manpower 
expenses. What we see within AHS-MRC is 
the same what our institution experiences 
every year. We have a number of posts that 
are not occupied and hence we have 
programs and funds unutilized because of 
that. Last year we had developed a bid for a 
clinical trials unit and we were assigned a 
huge operational expense but then no posts 
were approved so we ended up handing 
back the operational expense which would 
imply that we didn’t need it but the truth is 
that we needed the posts to use it. The 
major investment is posts and once we have 
that we can effectively use the money and 
demonstrate why we would need more 
money. 
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Financial Indemnity It has been through Legal review and 
comments are being addressed. It will be 
back then to procurement for final sign off 
and we hope to happen in the next month. 
It will only cover our institution. 
Reliance agreements One of the things that frustrate researchers 
in Qatar is that they have to apply to 
multiple IRBs if they want to have a 
collaborative research. One of the things I 
am proposing to the working groups is that 
we develop a reliance agreement for the 
whole country where then one IRB approval 
would cover all institutions.  
Regulatory systems MHRA had 2 calls and we need further 
discussions to see how much it would cost 
and the scope of work.  
Legal system for criminal liability We are setting meetings with key 
stakeholders to try lobbying against the new 
law. 
 
Saad: 
Are there any other barriers that we may have missed in the interview? 
 
Manager 1: 
No, I think those are the most important ones there. 
 
Saad: 
Anything else you would like to add relevant to this topic? 
 
Manager 1: 
To give you some context, what I did was that I calculated what proportion of the NHS 
budget is spent on research and development compared to Qatar. They spend 3 to 4 times 
(on a percentage basis) to what is spent in Qatar and most of that is spent on manpower.  
 
Saad: 
What percentage of that is exactly going to manpower? 
 
Manager 1: 
That would be about 70% of the total expense on R&D so like I said, critical mass of 
researchers is the most important requirement. That includes researchers, research 
nurses, infrastructure, training schemes, pathways and the clinical trial units.  
 
 
** The interview is concluded by thanking the interviewee ** 
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Manager 2 
 
** The interviewee is welcomed to the interview and briefed about the study ** 
 
Educational Background: Both 
 
Age: Between 50 and 60 
 
Saad:  
Could you please tell me about your role as the Executive Director of Research at your 
institution? 
 
Manager 2: 
As the Executive Director of Research, I am supposed to oversee all the research activities 
at our institution in general and that includes governance, funding, monitoring, auditing, 
training, reporting and involving heavily in shaping the research strategy at our institution.  
 
Saad: 
How many years have you been involved in this role? 
 
Manager 2: 
For more than five years since 2013. 
 
Saad: 
How would you describe the overall support for clinical research by the government in 
State of Qatar? 
 
Manager 2: 
There is an overall interest and goodwill to support research by the government. There is 
significant investment through availability of funds. However, from the government 
perspective, there is a gap in the expectation about what that fund could be translated 
into or what output could be produced through that investment. The expectation of the 
outcome of this investment is unrealistic and therefore this gap is widened. The 
expectation is high, the investment is significant however the means of meeting those 
expectations when it comes to having the right programs and right support services 
needed to implement to reach those outcomes are not properly in place. Also, the timeline 
for deliverables is not realistic. In my opinion, this reflects some immaturity in the system. 
It’s not unheard of, obviously, the ecosystem of research in Qatar is developing as we 
speak and typically it takes a couple of decades for such systems to develop and take the 
required shape. Five years ago, when I took over the research department here, things 
were much worse than now and I expect that in the next 5-10 years things will be more 
robust and developed. As you know I am departing this position soon and my successor 
will build on the current success. The major challenge in the past 5 years is the expectation 
from the investment which was significant but just enough to meet these expectations 
while the perception of the government is otherwise. The problem is that they did not see 
the outcome of this investment and this because the expectation was unrealistic on one 
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hand and secondly the means to transform this investment into outcomes wasn’t robust 
and well-structured or as coordinated as it should have been. 
 
Saad: 
Then how would you describe the support for clinical research within your institution? 
 
Manager 2: 
I think what I just explained applies to here as well however our institution itself had and 
continues to have its own set of challenges. If we look back a decade, we were not an 
academic health system but only a teaching hospital. We had residents and fellows come 
in for training and education but that itself isn’t enough to transform into an academic 
system. The research part was added later but even then, it was just a hobby or an option 
added to the mix. It was only recently that we adopted the tripod of research, education 
and health and things started to shape up since then. Firstly, we transformed into an 
academic health system with all the challenges that comes with that. As you know, any 
clinical research requires massive infrastructure to do proper research. People were doing 
clinical research at our institution in the past and continue doing but in an amateur way so 
bringing a new system was a great challenge. We are not a simple organization but a 
massive and complex organization which is unfortunately largely centralized. So, any 
challenge implementable to any other domain in the organization is also applicable to 
research, in addition to the set of challenges that are peculiar to research. Research is not 
looked at by its recipients as a necessity but a luxury and hence does not get enough 
attention. That said, and with the implementation of the new strategy and systems, 
significant investment has been allocated for research including funding and support from 
top leadership. The biggest challenge is the previously, and still, existing systems which are 
repulsive to conduct research at our institution. That translates into challenges in 
recruitment, procurement and career planning for researchers, recognition of research 
achievements – all these are not conducive to research here. However, things have 
improved and we tried to advocate for research agenda at our institution at different 
levels. 
 
Saad: 
How would you describe the infrastructure provided for clinical research at your 
institution? 
 
Manager 2: 
I don’t think its adequate. The amount of research you expect from a big organization like 
our institution and so diverse when it comes to the patient population must be much more 
than what is currently allocated. The footprint for research is small compared to the size of 
the organization. Another challenge is that the research space is scattered all over the 
organization in different buildings and facilities and that is not much helpful because when 
it comes to clinical research, there must be a close link to the clinical areas. The newer 
buildings have a small space allocation for research like the Ambulatory Care Center and 
the Qatar Rehabilitation Institute have areas dedicated for clinical research. I think those 
are good start and I personally believe that a decentralized hub and spoke model for 
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clinical trial units is the most suitable for us because of the diversity of the disease and 
patient population we manage.  
 
 
Saad: 
When we look at the funding, and I believe you have received grants from QNRF as well, 
usually you are awarded a certain sum of money but do you think that this money is being 
utilized fully or is it being used for purposes other than actual research costs? Do you think 
there is a sieve off effect in this process? 
 
Manager 2: 
At our institution, the concept of Indirect costs (IDC) is not fully understood. In general, 
IDCs are used in any given academic system to pour back into the system by buying time 
for researchers or allocating more resources in certain areas or centralized support funds. 
Here, the IDC until recently was being used for non-research purposes. It is very 
unfortunate that it was used for supporting other departments not involved in research 
but this is slowly changing now. The concept of “chopping off” funds for non-research 
purposes must be stopped and we must pursue better utilization of these funds into 
research purposes. 
 
Saad: 
How would you describe the overall attitude of clinicians towards research?  
 
Manager 2: 
I think it is mixed. Obviously when there is a funding opportunity to do what you like you 
jump on board but when it becomes too challenging people start to have second thoughts. 
I think we moved through different stages of no funds to very easy access of funds to a 
securitized level of funds and this is healthy, I think. As research advocates, we need to 
look into the challenges faced by those who hop on board for sake of research and try 
resolving if its related to training then we provide better training and if related to support 
teams then we provide them that too. The biggest challenge here, and I believe it’s not 
specific to our institution, is that the majority of the academic health systems find it 
difficult to distinguish between clinicians, clinical scientists and clinical research teams. So 
clinical research teams are not doctors who see patients but instead trained to do and 
support research while here I don’t think we provide that to our researchers. We expect 
them to do everything by themselves in addition to their actual duties. Even if we free 
their team, they would still not be qualified to do that because it’s not their job and they 
are not trained to do that. I think we need to allocate some funds so that they could then 
hire these support team members. For example if you allocate 100,000 USD for a project, a 
good portion has to be spent on bringing in qualified support team members doing things 
that the clinicians wouldn’t do like IRB follow up, progress reports etc. so it is the PIs job to 
ensure that these are up to the required levels but then not actually not having to doing it 
themselves. This is not a realistic expectation from a basic clinician. In my opinion I think 
the PI needs to spend more time doing the science than spending time on the operational 
part that is handled by other trained personnel like CROs. To be more efficient as an 
organization, we need to have our own core group of support that could be tapped into by 
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different researchers. The model of a central office to support all researchers was 
something I always supported but I was hit by a wall of challenges like policies and 
procedures not conducive to research support. I believe we need a central office with 
qualified CRCs, nurses, legal negotiators and so one who can provide full support to clinical 
researchers to be good and up to par when it comes to research governance. The IDC we 
talked about earlier could be used to support this central pool and researchers can pay for 
the time of these Central support staff from their research grants.  
 
Saad: 
If we look further into the clinician’s perspectives, what do you think motivates or 
demotivates them to do research? 
 
Manager 2: 
Most of the clinicians like to do research because it is challenging and challenge in 
medicine is always exciting and if they are able to do it without much trouble then that is 
good enough an incentive. The other motivation is the unique and diverse patient 
population at our institution which is attractive to do research and try to answer some of 
the scientific questions that are out there. In addition to that funding sources are very 
attractive – MRC, QNRF and pharma. Also, the vision of our institution and the country to 
support research is very attractive too. I think QNRF and many of its programs are a really 
good thing that happened to the Qatari research ecosystem.  
 
As for the challenges, the first is the perception of the importance of research at the 
management level needs a lot of work. Clinicians who are doing research do not feel 
rewarded or recognized for doing research. Unfortunately, on the contrary, some of them 
are looked at that they are doing nothing because they are doing research and this is very 
damaging. The second biggest challenge is allocation of time. Not all clinicians are very 
busy as some of them do have time to do research however there is a group of clinicians 
who are extremely busy and they are good at research and want to it but they don’t have 
protected time. The third challenge is the cumbersome processes we have for research 
approval, monitoring and reporting. We need to do a better job at this because we are still 
bureaucratic and need to be more efficient. Most, if not all, investigators do not like the 
IRB requirements in general but on the other hand they try to satisfy them. So, we, as 
administration, need to be more supportive and flexible and willing to revise our process 
to make it more conducive and attractive to the clinician researchers.  
 
Saad: 
Looking at the regulatory framework for research in Qatar, do you think that the policies 
are developed enough to support research? Mainly for the clinical trials that involve 
importing new drugs or investigational devices? 
 
Manager 2: 
I think it’s difficult to do clinical trials in Qatar because the regulatory frameworks are 
unfortunately imported from different places and put in one pot. It is very unfortunate 
that the regulatory framework imports all the difficulties of each system and combines 
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them all into one framework. There are also some of the regulatory issues that are not 
built on much science and evidence.  
 
Saad: 
Going back to the barriers you listed, I will start listing them again and you may propose 
solutions to these barriers, in your opinion. 
 
Barrier Steps taken to resolve 
Importance of research to clinicians Research advocacy and education efforts 
are ongoing. We could still do more. 
Repulsive admin systems A lot of effort has gone into that but in vain. 
More persistence and resilience is required. 
Infrastructure Research leads are now more involved in 
planning of facilities. The Translational 
Research Institute (TRI) project is brought to 
life again so hopefully we will have a good 
research center. There are good efforts to 
advocate for research space and facilities in 
the new projects. 
Lack of available trained research 
personnel and retention 
Some efforts started with HR but again we 
were sidelined due to other priorities at HR. 
We have to continue persistence and 
resilience. 
Differentiation between clinician, clinician 
scientist and clinical research teams 
Part of it is education and we need more 
research mentors at different departments. 
Protected Time  We raised it to the higher management but 
no progress so far. The solution is to keep 
persisting and resilience. 
 
Saad: 
Are there any other barriers you could think of that we did not discuss earlier? 
 
Manager 2: 
I think what we are going through is a natural process for a system trying to achieve 
milestones in development. We will take some time and things will happen as long as we 
don’t give up and be resilient and we don’t prematurely detour from doing this. I think 
there is a good umbrella that has been formed called the National Academic Advisory 
Board and areas of research are being prioritized. I think we are in the right track and we 
will achieve s long as the leadership keeps the vision and we don’t give up. 
 
Saad: 
You had a large part of your education and training outside Qatar and also many 
interactions during your professional experience as a researcher. Do you think that these 
barriers are specific to Qatar or is it similar in other systems elsewhere? 
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Manager 2: 
It is not unique to Qatar for sure. Trying to work in a hospital transforming to an academic 
health system is not unique to here. Academics think alike and non-academics think alike. 
Our system is trying to establish itself and there are more established systems around the 
world but when comparing ourselves to any developing system, we are ahead of them. 
One of the reasons why we are ahead is that we allocated huge funds and that brings in lot 
of resources. Unfortunately, the funds have been allocated but the systems are not fully 
developed so there is spillage. Improper utilization of funds will not lead us to where we 
want. Some of the systems I have evaluated have the right set of regulations and 
operations but lack funds – we are the other way around. Some of the more mature 
systems, their challenge is not operational but how to secure more funding and then use 
that fund to achieve better outcomes. This is like the difference between minor and major 
leagues. We are at the beginning of the minor league and not in the major league. I believe 
it is healthy to look at ourselves as a developing system in the minor league and one thing I 
learnt from this experience is that you can call yourself whatever you want but people will 
see whatever they see. You can say you are the best in the world but if you aren’t and the 
people are not seeing it, they will tell what they see.  
 
Saad: 
Do you have any further information that you think will benefit the topic of my research? 
 
Manager 2: 
I think if you encompass what I said in a systematic way, it will give a whole picture. 
 
 
** The interview is concluded by thanking the interviewee ** 
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Manager 3 
** The interviewee is welcomed to the interview and briefed about the study ** 
 
Educational Background: Both 
 
Age: 50 to 60 
 
Saad:  
Could you please tell me about your role as a research lead? 
 
Manager 3: 
I am the assistant dean for clinical research at our institution and also run the clinical 
research core. At the core, we run and support clinical research across Qatar particularly in 
collaboration with other institutions. 
 
Saad: 
How many years have you been in this role? 
 
Manager 3: 
Almost six years now.  
 
Saad: 
What aspects of this role have you been involved in? 
 
Manager 3: 
When I first arrived, there was no infrastructure for clinical research at our institution or 
the country so we setup the infrastructure from beginning including equipment, personnel, 
SOPs, policies etc. necessary to conduct good clinical research. So, I have been involved in 
all aspects of setting up clinical research from the ground up – from having nothing to 
become a good organization for conducting clinical trials.  
 
Saad: 
And I believe you have been successful so far in doing that? 
 
Manager 3: 
There are challenges in the country. We are considered one of the successful groups but 
there are challenges obviously. We have succeeded in the infrastructure that we set up.  
 
Saad: 
How would you describe the support for clinical research from the government of Qatar? 
 
Manager 3: 
The Ministry of Public Health (MOPH) has guidelines for human and animal research. There 
guidelines are based in the American system and that is the main support provided. Apart 
from that there are individual institutions with their own structures and governance like 
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IRBs, DSMBs and so on. The support has been mainly to set the framework of how we do 
research however just setting the framework isn’t sufficient. To succeed, they should 
develop pathways on how to implement the framework and how the institutions should 
work together. Unfortunately, and I am being honest here, the approach has been that 
clinical research is “bad” to do. The idea is that who is doing clinical research is doing 
something dangerous or difficult. To stop this danger, more regulations have to be in place 
whereas actually these regulations are stopping people from doing good things. There 
needs to be a balance for things to succeed and right now I think that balance isn’t there. 
 
Saad: 
How would you describe the support for clinical research within your institution? 
 
Manager 3: 
Within the institution the support for clinical research obviously it is a medical school with 
teaching and hence it supports clinical research however it is the way the institution has 
developed. When they started there was a big emphasis on basic research and hence the 
clinical research is like a new kid around the block who is always trying to do extra things. 
The institution is catching up with the need to do more clinical research.  
 
Saad: 
How would describe the funding at the national and institutional level for clinical research? 
 
Manager 3: 
Qatar is not a poor country, that’s a given. It has given money to solve problems through 
clinical research however the grants system is not designed for clinical research and 
particularly clinical trials. We have a limited funding because when there is cap, you can’t 
answer all the questions your research was exploring but that is not possible in 800,000 or 
1 million. Similarly, when there is a budget cutdown from the awarded grants by the 
funding agency, they can’t do that for clinical research because it is not like basic science 
where you can adjust to budget revisions by doing less experiments. However, in clinical 
research, when you have to recruit 1000 patients then there is a specific cost required to 
reach that target and revisions are not serving the purpose here. There is impatience about 
spending and getting outcomes but the reality on the ground for the investigators is that 
they have to get all approvals from different IRBs and different hurdles that they have to 
go through and the funder is frustrated because they think you are not doing but it’s not 
the investigator’s fault here. The process of funding now is that I should have all the 
approvals in place to be able to start using my funding and if I didn’t then they go punitive 
on the investigators. To make that happen, every institution has to agree to expedite the 
approval process within that time frame. Another barrier that we faced is that we have a 
grant with the money in place and approvals from two IRBs but then someone at MOPH is 
not happy about it so they decide to stop everything and we have to re-do the approval 
process again. The problem is that when we came back with the required revisions to our 
IRB, they requested further changes and doing research is getting more difficult now. 
These approaches are not conducive to doing research. Another thing done in Qatar is that 
you need to have your CRF stamped – which is a working document that should be allowed 
to change or re-arrange to be suitable to the way you are collecting your data. If its 
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stamped once and you change one sentence, you have to re-stamp the whole document 
again by both IRBs. The other issue is conflict of interest that has to be submitted 
repeatedly to all IRBs and annually for each PI and each project. This could be avoided by 
just having an annual COI general to all projects or an indefinite COI where the PI is only 
required to report it in case of any change in his status. I am not against declaring COI but 
it should be only as and when required. Again, this takes us back to the American system 
being replicated here but unlike here, they have many startups or sponsors for research 
projects and researchers are actively holding shares or promoting these companies.  
 
Saad: 
How would you describe the regulatory framework when it comes to the policies and 
guidelines governing clinical research? 
 
Manager 3: 
It is very challenging as every institution has their own guidelines, rules, paperwork, way of 
doing things and pathways for reporting. 
 
Saad: 
Why is this inconsistency happening, even when all of them are under one regulatory 
umbrella? 
 
Manager 3: 
It is not actually regulated. We need someone who really understands clinical research at 
the Ministry to be able to harmonize processes. This requires expertise, flexible mind, 
planning and understanding of the clinical research environment in Qatar. The idea is to 
facilitate while maintaining subject safety so this balance should be maintained and for 
that you need someone who does clinical research. Then the IRBs could be harmonized to 
follow one standard procedure and paperwork. 
 
Saad: 
Or would you rather advocate for a national IRB? 
 
Manager 3: 
The problem with the national IRB is that if its run by the Ministry then it gets bogged 
down and things get delayed. I think institutions should be able to decide whether their 
investigators are good enough to do research, the facilities required and so on and the 
institutions should be powerful enough to do that. If a national IRB is independent of the 
ministry, again it’s a committee and it requires individuals, managing personnel, funding 
etc. I can see other countries in the GCC where the national IRB isn’t succeeding and 
getting bogged down because the committee is formed by people who don’t know what 
they are doing.  
 
Saad: 
How would you describe the overall attitude of clinicians towards research? 
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Manager 3: 
The problems here are very similar to elsewhere. People do research to get it on their CVs, 
promotion, bigger pay, prestige but the reason they should be doing research is that they 
have a question that they need to answer about their patient cohort or they want to 
change clinical practice of how we do things. Attitude wise, clinicians are very open to 
doing research but looking at the history, research meant extra money in the pocket but 
that’s not happening anymore so the people who did it for money are not doing much 
now. Hence, we are getting people who are more passionate about research itself but the 
problem with that is that they are clinically busy so they cannot really focus on doing 
research. One potential is going back to the UK model where you buy clinicians time for 
doing research hence you charge, for example, 20% of their time to the grant and 
somebody else is brought in to do their clinical time while they have time to do research 
instead. That will really help everything. Everybody’s job description must have outlined 
portion for clinical duties, research, teaching and administration. If this happens then 
research will become a part of their job and if it’s their job then they will more likely do it 
better.  
 
Saad: 
In the course of this conversation, you mentioned few barriers like multiple IRBs, funding 
limitations by QNRF, COI declaration. Can you mention some other barriers to conducting 
clinical research in Qatar? 
 
Manager 3: 
Organizational competition. Qatar is a wealthy country but the population of Qatar is small 
and the number of Qatari researchers is even smaller. People involved in clinical research 
come from different resource limited countries and have different agendas. As soon as 
they come, they think that they have to fight and hold on to the resources and look better 
than the other institution so one needs to do more collaborative work. We have to work 
together because when there is institutional competition, then money gets wasted and 
things don’t progress but this is happening less now. 
 
The other barriers in clinical research is the patient population because the population 
here is mostly transient and expatriate. It is therefore hard to have long term clinical trials 
because their jobs may not be secure to allow long term follow up. The other challenge is 
that when we started reporting (unrelated) adverse events, some IRBs are shocked to see 
that because they think something bad is happening. Most of the studies here are fairly 
simple and hence this concept of seeing SAEs being reported is not very developed. There 
is a lot of education and training that needs to be done in terms of what clinical research 
looks like, how they are reported, SAEs, AEs, pathways that can be harmonized. 
 
I started this conversation some time ago to harmonize pathways with HMC as a start but 
it was blocked at various levels because people don’t want to work together.  
 
Saad: 
What about the infrastructure? 
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Manager 3: 
It is not well developed else we wouldn’t be having this conversation in a temporary office. 
Big clinical organization should have better infrastructure when it comes to policies, 
guidelines.  
 
There is also the barrier of lack of space. When we do a study at a clinic, the rooms change 
frequently and we can’t have a stable environment to do it. Most countries have clinical 
research center geared up with nurses and it is done in a slick way. I don’t know why Qatar 
does not have a good diabetes research, for example, since it is the biggest health problem 
here.  
 
Saad: 
Why do you think this is not happening? 
 
Manager 3: 
I think this depends on the leadership. Many countries in the world count on the advisors 
and depending who the advisor is, at that time, it changes how things work. In US and UK, 
there are companies, lobbying senators and things like that so Qatar is going through the 
same because the government wants to do the best for their people but they can only go 
on with certain levels of advice. We should be allowed to make mistakes and learn from 
them. If we look at countries with thousands of years of history, they made all the 
mistakes. It’s a part of developing and it’s not easy to have everything at one place in one 
go. Things can happen faster here, it’s not that they don’t want to do it. 
 
Saad: 
Talking about funds, let’s say that you are awarded a million dollar project by QNRF, do 
you think that the funded amount is being effectively used for research or is there a 
wastage or sieve off effect in using those funds? 
 
Manager 3: 
There are specific issues with being in Qatar. For example, if you are hiring a post-Doc, 
then you need to pay for their housing, education, leaves etc. in addition to their salary so 
a post-doc in the US might cost you 60,000 dollars but here it is around 200,000! The cost 
of hiring personnel here is much higher here than elsewhere. If you have a grant with 
limited funding, then the post-doc takes most of that budget and nothing is left for 
consumables and other items.  
 
Saad: 
So, the barriers you mentioned, are these specific to Qatar? 
 
Manager 3: 
Some are specific and some are not. The specific ones are stability for example, as we 
don’t have people long enough who can change things. Qatar is advanced compared to 
other GCC countries. It is amazing to have QNRF unlike any other country but the problem 
is that money was given at times when the infrastructure wasn’t there so the money could 
have been wasted back then. Because of this wastage, the management system has 
88 
become so rigid that we can’t do anything now with the money. In the UK, when you are 
awarded a grant, we have the flexibility of moving money around and go to where science 
leads us but here, we can’t do that. We are stuck as we have to do exactly what we said we 
will and of don’t we are punished by points, suspensions etc. Science does not develop like 
that but instead we have something that develops into something else that might lead us 
to a new direction. It is good, if the PIs are good project managers only. 
 
Saad: 
Do you think there is any gap between the investments and the expected outcomes by the 
State when it comes to funding? 
 
Manager 3: 
Absolutely. However, when we look at the funders, they have to report somewhere higher 
about the outputs of this funding. Outputs can be publications, new IP and all that but 
science does not always produce these outputs, not right away at least. For example, it’s 
not realistic to expect papers out of undergraduate funding projects. The other thing 
introduced is the co-funding that could be managed differently. If an institution wants to 
co-fund ten million dollars, they put in the same pot as QNRF specifying the priorities and 
the funds come from one place. There is no need for multiple co-funding applications and 
agreements as it happens now.  
 
Saad: 
I will now list all the barriers you identified and you may propose some solutions to these 
barriers.  
 
Barrier Proposed Solution 
Multiple IRBs Reliance agreements among IRBs, 
Harmonized pathways and paperwork, 
Reporting 
Funding limitations Reduce wastage. For example, anything that 
can’t be done in Qatar is immediately 
outsourced rather than building capacity to 
do that work within Qatar.  
(Transient) Patient population There is nothing much we can do about 
that. When we design the study, we over 
estimate dropout. Also, we avoid the 
extended holiday season including Ramadan 
and summer vacation specifically when the 
study involves a drug that could raise safety 
concerns. It is easier to do short term 
studies in this case. 
Organizational skills Harmonization is the way and avoiding 
duplication of efforts. 
Education for researchers It could happen at the organizational and 
individual levels. We are trying to set up 
courses but it always comes with 
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experience. There must be flexibility in the 
system to allow people learn by making 
(limited) mistakes and learning from them.  
Protected Time I believe our institution has the funds to do 
that. We could identify young talents 
interested in research and clinical practice 
to buy their time for doing more research 
and have pathways for career development 
as clinician scientists.  
Infrastructure Unless the organization decides what they 
want to do and how they are going to do, it 
won’t happen. There is a need for a building 
for clinical research. 
 
Saad: 
You mentioned in the beginning of this conversation that people think that doing research 
is a bad thing or people do it for fun. Where do these perceptions come from? 
 
Manager 3: 
Because there have been errors on research but there are errors in clinical service too. 
There are errors in doing everything, even bus driving. There must be systems to reduce 
these errors but then we don’t look at people as bad or doing something for their own 
benefit. People do research because they are passionate about patient care. If patient care 
improves, that is a very good thing. For example, one of my studies on diabetes had a very 
positive outcome where 91% of the people who were diabetic are not diabetic anymore. 
This could impact more thousands of people. Papers are good but there are people who do 
it just to improve the life of their patients. Sadly, there are people who do it for other 
reasons as well like money or fame. The responsibilities ate research are not only clinical 
but involve research aspects as well. These are enormous responsibilities especially when 
you are doing research with safety implications. It is burdensome because if you are 
clinician you work for fixed hours unlike research where you might get called at the middle 
of the night because of someone having an adverse event related to your research study. It 
is much more stressful and complicated. 
 
Saad: 
Do you think that the outcomes we’ve had from the ongoing and completed studies are 
translated into clinical care for the patients as treatments or national programs? 
 
Manager 3: 
Let’s look at QNRF for example. In the earlier themes, a project would get funded for a 
disease that is rarely seen in Qatar but just because the submitting PI is a renowned 
researcher in the world. Recently the calls are more focused to the country’s needs and 
the same needs to happen with other institutions. Also, we have to fund studies that will 
have impact and avoid duplication of studies already done many times elsewhere. 
Scientifically each department needs to identify their priority areas not because it is 
attractive but because it is important to the community in Qatar.  
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The issue of generating publications but not making to patient practice is happening 
everywhere else too but there is something called rapid deployment. The Ministry has to 
look at some studies and decide to rapidly deploy them into practice rather than waiting 
for more evidence like the study I told you about earlier in this interview. Rapid 
deployment of these outcomes will change things. 
 
Saad: 
With all the mentioned barriers, how would you rate the readiness of the system to 
conduct clinical research? 
 
Manager 3: 
This is a difficult question. If by research, you just mean collecting of questionnaire data 
and blood samples then it’s a ten but for clinical trials it’s probably five or six out of ten.  
 
 
** The interview is concluded by thanking the interviewee ** 
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Manager 4 
** The interviewee is welcomed to the interview and briefed about the study ** 
 
Educational Background: Both 
 
Age: Between 50 and 60 
 
Saad:  
Could you please tell me about your role in the Research leadership in Qatar? 
 
Manager 4: 
I am the manager for department of research at our institution. Our function is to develop 
national regulations and policies that govern ethical conduct of research on Qatar. 
Consequently, we have developed a number of policies and regulations that have been 
posted on our website. 
 
Saad: 
How would you describe the support for clinical research in State of Qatar? 
 
Manager 4: 
Qatar has a very ambitious vision when it comes to research in general and clinical 
research in particular. So, when it comes to clinical research, there are a number of clinical 
research projects going on currently mainly at Hamad Medical Corporation as the primary 
hub for patient care in Qatar. To fulfill the regulatory requirement for the conduct of 
research, we have developed a number of policies. We have protection of human subjects 
involved in research and it is adopted from the 45 Code of Regulation 46 of the US 
regulation. The policy itself mainly addresses the function of the IRB committee, review 
conduct, review types and the elements of informed consent. We also developed policy for 
the conduct of clinical trials and its adopting ICH-GCP guidelines. 
 
Saad: 
Is there any clinical research going on within your institution? 
 
Manager 4: 
Not within the institution itself because we are a regulatory body however research takes 
place at hospital setting like HMC, private hospitals, academic research institutions located 
within Qatar Foundation. 
 
Saad: 
How would you describe the funding support provided by the State of Qatar for clinical 
research? 
 
Manager 4: 
There is a single funding organization which is the Qatar National Research Fund (QNRF). 
The fund is distributed on a competitive basis and each researcher/ institution submit their 
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proposal to QNRF and they will send it to external reviewers. Each proposal is valued 
according to its purpose and how it is addressing one of the national research priorities. It 
is a very competitive procedure but we can guess what is the result because the fund 
distribution is among four pillars – health, ICT, Social sciences and Energy. The majority 
fund goes to Qatar University as a national university followed by Texas A&M- Qatar and 
the remaining to WCMQ, HMC etc. 
 
Saad: 
Do you think that the funding allocated for clinical research is sufficient in this case? 
 
Manager 4: 
There isn’t enough fund allocated to clinical research because Qatar is not that advanced 
un submission of clinical trial proposals. So far, we manage only phase 2, phase 3 and of 
course phase 4 trials however phase 1 trials where there is a new investigational drug or a 
device are very few, almost rare. Therefore, there isn’t a chance for QNRF to fund these 
proposals. 
 
Saad 
What about the facilities and infrastructure for clinical research? 
 
Manager 4: 
Most of the hospitals such as HMC and Sidra are in the process of developing their 
infrastructure to build clinical research units however there are lots of barriers when it 
comes to budget, human capacity etc. so the progress in this area is very slow. 
 
Saad: 
How would you describe the overall attitude of clinicians towards clinical research in 
Qatar? 
 
Manager 4: 
Physicians are very keen and interested in conducting research however there is no 
protected time for them to conduct research. Places like PHCC and HMC don’t provide 
protected time to their physicians for doing research. Therefore, it does affect their ability 
to submit and work on these proposals. Also, there is always problem of hiring personnel 
to assist physicians in their research endeavor. There are very strong barriers on dealing 
with HR to hire part time research coordinators, CROs etc. so it is hard for clinicians in 
Qatar to practice research. 
 
Saad: 
Despite of all the barriers, we still see clinicians undertake research so what do you think 
motivates them to do that? 
 
Manager 4: 
Clinicians will always be interested in having their names in the publications. Also, they 
really like to help their patients. Research is always a tool to provide their patients new 
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treatment, new diagnostic methods or prevention from diseases hence it gives them good 
feeling to conduct research. It is important for their professional growth. 
 
Saad: 
How would you describe the perception that some clinicians have of their fellow clinician-
researchers that they are doing it as a “luxury”? Or maybe compromising clinical service to 
do research? 
 
Manager 4: 
This can happen in advanced countries like the US where the clinicians are actually away 
from their clinics for a certain period in order to do research. However, in Qatar we are not 
at this stage yet and clinicians have to work full time to see their patients along with doing 
research so I don’t think it is a luxury in this case. 
 
Saad: 
You mentioned that the policies and regulations have been revised recently. How frequent 
do these revisions happen? 
 
Manager 4: 
We understand that there are always new things happening when it comes to protection 
of human subjects and policy making so we are always keen to look at international 
standards for best clinical practice. We look at the most recent regulations at US, UK, 
Canada just to make sure that procedures for human subject protection are in place, well 
updated and recently we introduced new consents applicable to all stem cell and genomic 
research in Qatar. We are always in the process of updating our policies to add anything 
new and relevant. Also, to gain public trust, we need to ensure that their rights are being 
well maintained.  
 
The revisions are hence, as and when needed, and the process for policies development 
and regulation has to be approved Qatar National Research Ethics Committee. It a national 
committee that was issued by the Minister of Public Health. The main task of this 
committee is to review the policies and regulations and ask us to update them to address 
any controversial research issues that may arise in any institution like incidental finding in 
genetic research for example. It is the governance body that approves national policies and 
regulations.  
 
Saad: 
From previous interviews, there were comments regarding submission to multiple IRBs 
and concerns that Qatar, due to its relatively smaller geographical size, should have a 
single national IRB. Being the regulatory department, why do you think are these 
inconsistencies in the work of these committees? And could a national IRB solve this? 
 
Manager 4: 
We did a very good job in developing a systematic model for the registration of IRB 
committees and providing assurance to these IRBs to adhere to the terms and functions 
stated in our policies and regulations. Having multiple IRBs is a normal situation as seen in 
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many developed countries that conduct human research. However, considering the size of 
Qatar, it is true that a national central IRB committee can do the job and save a lot of time 
and effort. We wanted to empower the local institutional IRBs in doing their job in 
protecting its own patients as it comes to protection of the subjects within a hospital like 
HMC or Sidra for example. The matter of having a single IRB has been discussed many 
times. It is in the pipeline to develop and was submitted to the Minister’s office however 
there was no budget for it. We would like that local institutions contribute to that budget 
and efforts could be articulated to build this national committee because the members for 
that committee will be from those institutions like HMC, Sidra, WCMQ etc. We have many 
experienced IRB members in those committees and I don’t see any obstacles in initiating 
the central IRB except the budget required for this project. 
 
Saad: 
Going back to the funding, do you think that the funding allocated by the State of Qatar for 
clinical research is being effectively utilized or us there a wastage occurring at any level? 
 
Manager 4: 
Duplication of research topics and following anything done elsewhere and doing that same 
on Qatari population claiming that its new because the population is different is really a 
waste of time and effort. QNRF should do a better job in avoiding these duplications and 
follow up throughout the process if a project is progressing well. I believe the one or two 
reports are not good enough for the evaluation. They should have the power to terminate 
such proposals if not progressing within the timeframe. I think they lack the number of 
staffs who can meticulously monitor the research activities and its outcome and translate 
the outcomes into better use at the national and institutional level. This is a huge gap that 
the funding body is not following through. When it comes to institutional funds, there 
should be a very efficient mechanism to look into the submitted proposals and outcomes 
and if it’s going to improve the prevention, diagnosis and treatment of certain diseases or 
not. We are coming to the point that a lot of money is being spent but the MOPH is not 
seeing any tangible outcomes that will improve patient’s lives or help us in policy making. 
 
Saad: 
Do you think there is a gap between the expectation from the investment in research and 
the outcomes in reality? 
 
Manager 4: 
Qatar has invested massively into research and there has been a tangible growth when it 
comes to building the human capacity over the last ten years. The MOPH did an 
assessment of the research activity in Qatar and we saw that the number of researchers 
has grown exponentially. The same applies to the publications and citation index which 
shows how efficient the outcomes and publications are. Qatar is becoming a very 
advanced place above other regional countries. However, there is still room for further 
progress and growth. 
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Saad: 
You mentioned few barriers during the interview like protected time, funding, 
infrastructure, administrative barriers like hiring personnel. Are there any other barriers 
that you think are faced by clinical research in Qatar? 
 
Manager 4: 
I see some of the research institutions are placing a lot of barriers under the name of 
regulations and I really believe that IRB committees decisions and review process should 
be in place for two main purposes. First, for human subjects’ protection and the second to 
help the PI’s by reducing the burden of regulations. Qatar should be a hub for international 
clinical trials. The fund should be provided to build infrastructure like clinical trial units and 
to hire staff to help putting Qatar in a better place for clinical trials. I believe Qatar can 
take a lead in the region with all the systems and support we have in this field. Many 
pharma companies approach Qatar for phase 2 and 3 because of the established system 
we have here. When it comes to hiring staff, this and other administrative barriers should 
be addressed within the institution itself and I believe that the management should be the 
focal point of contact with the authorities to request more budget for personnel, 
infrastructure etc. 
 
Saad: 
Do you think that the outcomes of the research projects are being translated into clinical 
care or national programs that would help disseminate information to the public? 
 
Manager 4: 
As I said there is a gap in the area of translating research outcomes from bench side to 
patient side. There is a huge gap in finding outcomes from the submitted or funded 
proposals and trials. Everybody is working in their own corner without really connecting 
the dots of the beneficial research that is going on. I think the funding body plays a huge 
role in making that connection. The research institutions should reach out to the MOPH to 
inform them about the outcomes of their projects that could help improve the patient care 
or changes in the national policies.  
 
Saad: 
Is this not happening at all or happening at a limited scale? 
 
Manager 4: 
It is not happening at all right now. There is a recent attention towards this but there is no 
defined mechanism on conducting this process. 
 
Saad: 
How would you describe the readiness of the system in undertaking clinical research? 
 
Manager 4: 
There has to be a very well-established training and education program to keep reminding 
a clinician about the ethics of research. We have the CITI training which is a very basic 
training for physicians who conduct research however it is really the institutional 
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responsibility to have a very well-established training program and to have a record of 
these being provided to the investigators. They have to ensure that the investigators are 
well trained and transfer this knowledge to their teams and ensure every personnel in 
their team understands the regulations. 
 
Saad: 
Is there anything else that you would like to add relevant to the topic that my research is 
addressing? 
 
Manager 4: 
I think we need a lot of research needs to be conducted similar to the one you are doing 
now to continue assessing the current framework and matrix of clinical research in Qatar. 
Not only clinical research but also for social and behavioral research too. We need to 
assess the conduct of the research activities and how to transform the outcomes into 
policy making and patient care. Such research provides evidence-based data that will help 
institutions and governments to formulate better policies.  
 
 
** The interview is concluded by thanking the interviewee ** 
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Manager 5 
** The interviewee is welcomed to the interview and briefed about the study ** 
 
Educational Background: Both 
 
Age: Between 50 and 60 
 
Saad:  
Could you please tell me about your role in the clinical research leadership in Qatar? 
 
Manager 5: 
I am involved in both phases - pre-award and post-award for grants at our institution. In 
the pre-award, I do the initial reading, identifying key words, assigning reviewers, similarity 
checks and the screening process. We receive the short-listed proposals that go through 
the programmatic review and my role here is more influential because I am a voting 
member. In this review we go through the nitty gritty details to ensure that the idea will be 
feasible in Qatar because the reviewers are usually external and not aware of the 
environment here. The scientific reviewers look into the science and the novelty while we 
look at the duplications, feasibility, performance of the team and other factors. For the 
post-award of funded projects, my contact would be every six months for reviewing the 
progress report and releasing the installments. We identify the progress and weaknesses 
(if any) even if overlooked by the Lead PI to ensure compliance with our policies and 
guidelines. 
 
Saad: 
How would you describe the support for clinical research in Qatar? 
 
Manager 5: 
In general, I think it’s amazing compared to my background in the United States where the 
financial aspect was very challenging when it comes to getting thousands of dollars while 
here, they are very generous at all levels. This is from the financial aspect. From the legal 
perspective, I think it is the challenging part because it a nascent research culture. There is 
not much maturity in the legal system for research. As of today, I don’t see any legal 
framework for research. We reviewed a draft a couple of years back but I am not sure if it 
was implemented but then it is important before we release millions of dollars that we 
have a legal background to support it. We started building this when we are almost ten 
years into awarding funds and that too was partially built on a trial and error basis by 
looking at the US system if it’s doable in Qatar to apply the same. This means that there 
was no homework because it there was a background work done, there would have been 
an evaluation of the policies for their feasibility in Qatar before even releasing them. That 
created a lot of challenges to the investigators because after going through long phases of 
review and evaluation, most of them face difficulties with the IRB approvals. I see that it’s 
not their problem alone because the proposals have been through the Research Office 
(RO) before reaching the review stage and hence the RO is aware of the ethical 
requirements needed initially and the expected load. All these things have to be assessed 
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before submission but usually this does not happen and the proposals then have to wait 
for six months to get the IRB approvals. Even for expedited review it takes a couple of 
weeks while actually it should be done in 48-72 hours because sometimes clinical trials 
involving patient safety can’t wait that long. We need this interactive culture that is well 
equipped. Coming from Stanford University which is a very well-established clinical 
research facility, what I faced here was that there were no ethical committees that were 
well equipped with DSMBs for example. I had to specify for each awarded project that 
required DSMB and I think they would have gone ahead without it if I didn’t do that. I 
recommended many times to have the IRB submissions prior to the QNRF application and 
many institutions in US do that because this would save a lot of time for the investigators 
and the reviewers. If this happens, then everything will be already in place if the project is 
awarded and they can start immediately without further delays. I think this will be a very 
good step if we want to improve this aspect. 
 
Another issue is the infrastructure. For example, the vivarium at Qatar University (QU). The 
promise was to be functional by 2014 but as of now it does not accept all the animals that 
were promised initially for research. So, what happens is that when we receive the 
proposal for evaluation, the investigator says that the animal work will be done at QU 
vivarium but later after awarding, their application to QU gets rejected because they don’t 
have that specific type of animal required for the research. Eventually the investigator 
changes the whole plan and decides to do the animal work outside which defeats our 
purpose of building research capacity within Qatar. So, we lose the value of helping the 
Qatari research culture and the money because its going outside Qatar. I think if we look at 
the millions of dollars that are being diverted to outside Qatar because of this limitation, 
then the management of the vivarium might need to reconsider their decision about the 
list of animals that they provide and extend it further. Also, the cost is unusually high 
compared to the cost of performing the work outside and I am not sure about the reasons 
behind this. It could be due to the current embargo that Qatar is facing from its 
neighboring countries but still it shouldn’t be this high.  
 
Also, there is the issue of access to data. For researchers being able to submit a project, 
they need to have some preliminary data about the population and the disease 
prevalence. Initially, the system here was very conservative when it comes to data access 
because there was no Cerner available and any access for data needed many stages of 
approval. To go around this, the researchers used data from outside Qatar, which could 
sometimes be unreliable, to build their proposals and this is not right. Lack of 
epidemiological studies relevant to Qatar was a very big challenge. Even after we started 
having studies, there were issues with access to the data from these studies. Currently 
with Cerner and Qatar Biobank there is a lot of improvement in this regard. The quantity of 
accumulated data is massive to make it a reliable source.  
 
Saad: 
And how would you describe the support from your institution for clinical research? 
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Manager 5: 
Our role is a mediator but not a problem solver. However, we are able to identify the 
challenges if we get a glimpse of it and link them to the solution. For example, the first 
issue I raised when I came here was having access to data from private and public hospitals 
because having the public hospitals data alone would not be representative of Qatar 
because as you know most Qataris depend on the private hospitals. This issue is still 
ongoing however with Cerner, I hope they link it with the private hospitals and then access 
to data would be simpler and wider. We go through these kinds of difficulties and keep the 
as lessons learnt to take opportunity and raise it in any meetings to improve these issues. 
However, things are going forward but slowly and I think they could go faster with some 
sincere efforts and devotion to resolve these issues because time is precious and other 
countries are developing quickly in improving the health of their populations. The 
challenges are sometimes beyond the capacity of the researchers and as a funding agency 
we sometimes communicate with stakeholders through meetings and events but then our 
communication is limited to certain issues only as we cannot intrude ourselves in details or 
internal institutional issues. We try our best but then we cannot promise to resolve 
everything. 
 
Saad: 
How would you describe the funding for clinical research in Qatar? 
 
Manager 5: 
As mentioned earlier, the funding is generous but identifying the priorities needs more 
work. We didn’t get any tangible outcomes like we didn’t solve the diabetes issues; we 
didn’t even come up with a new biomarker and this takes years to happen. As you know, 
drugs take 12-15 years until they make it to the market shelves. We started in 2007 and we 
haven’t reached there yet, assuming that we have something discovered something 
promising in 2007 however there is progress. We started from zero and with all my due 
respect to the research happening in different institutions, it’s not really focused the way 
we wanted to focus on Qatar. What we see in these institutions is that the researchers are 
working based on personal interests and their research background so the contribution to 
the research in Qatar is limited in this case. Of course, there are common denominators 
when it comes to common knowledge and skills but excelling in research requires focus for 
long years to make a difference. I hope we have a tangible outcome within next 5-10 years 
but as of today, it’s too early to say did a difference with the funding spent. We are 
generously funding the priorities which are defined based on data generated over the 
years and relied on the MOPH data however we don’t have many epidemiological studies 
in Qatar which is something very challenging to identify weaknesses and gap analysis. I 
think we did very well, given the limited resources we have and tried to fill all the gaps. 
This year, for example, we expanded the limits and widened the topics so we hope to 
receive more applications.  
 
Saad: 
Going back to what you said about tangible outcomes, there have been views by other 
managers that the expectations that the funders have from their “modest” investments 
are unrealistic. Would you support this statement? 
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Manager 5: 
Well it depends on how big is your dream because if you are determined to make a 
difference, then you will regardless of how much you have. You have to be creative. From 
where I come from, we have been through difficult times as a country where we burnt 
tires to make bags and move on. Need is the mother of inventions and God gave us this 
creativity and mind to adapt and excel with the little we have. I believe many of them are 
spoilt to the extent that they just need fresh money coming every time so they don’t need 
much effort to be creative and trying to get the most of what they have. If you have a 
dream worth 3 million dollars but you have only one million dollars, you will adjust it in a 
way to make the most of what you have in hand and then build a case for getting the 
additional funding or maybe divide your dream into phases. If you show that your proof of 
concept is promising, I guarantee you that we will fund the remaining stages of your 
project. We have been very generous initially and we didn’t make much out of it. We 
understand that there were challenges but the promises that we got were very 
disappointing eventually. There was the exceptional grant that was awarded for five 
million dollars but then the results were not as expected because they faced many 
challenges related to cultural issues that could have been avoided if this was taken into 
consideration during the design stage. The challenges faced by this project is one of the 
main reasons why we introduced the programmatic review after the scientific review to 
ensure feasibility of implementation in Qatar. We have other exceptional grants with 
similar funding and we hope to have some outcomes out of them in future. 
 
Saad: 
How would you describe the attitude of clinicians towards clinical research in Qatar? 
 
Manager 5: 
God be with them, given the limited time they have! Since day one, I have been advocating 
for protected and since HMC is the teaching hospital for WCMQ and QU, this is very 
important. In other parts of the world, people usually kill themselves to go to teaching 
hospitals to get more time for research. There must be a minimum set protected time for 
research, around 20%, because you will never progress without research. Unfortunately, in 
HMC there is no protected time. The clinicians have so many beautiful ideas and they are 
sincere to make it happen but they do not have time and I canty blame them because their 
first job is the clinical service. Hence an increase in manpower is required to have at least 
20-40% of protected time for research. Without having quality protected time for research, 
I cannot blame them that much for not performing better. I don’t see much also because 
most of the them are trained to be clinicians and not researchers. In the modern medical 
degrees, a lot of research component is included within the education and it’s the 
approach in getting knowledge that gives them research experience. Such systems give the 
freedom of being creative in doing things in a new way not done by someone earlier 
because each one of us has their own unique way of thinking and applying. In the US, no 
matter where you come from, you need to complete a rigorous training before you start 
any research even when you move from one state to another. I wish we had something 
similar here in Qatar and if we have it now, I am not sure about its quality. I think everyone 
should complete a training to be qualified as a clinician scientist. 
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Saad: 
Most of the trainings you mentioned are for the post-award aspects of research projects 
but what about training to write research projects and grants? 
 
Manager 5: 
Yes, definitely it is required because sometimes even whole reviewing I come across 
proposals that are poor even grammatically and this affects the quality. However, it’s not 
much different in US but they have technical writers in each department or institution who 
are responsible for writing grants or reviewing written proposals for further tweaking and 
fine tuning to make it appealing to the reviewers because the way of presenting an idea is 
very important to get funding. Hence as a scientist you would then focus on the idea and 
leave the writing and these details to the technical writers.  
 
Saad: 
Even with all the barriers you mentioned, we can still see a lot of proposals submitted by 
clinicians. How would you explain that? 
 
Manager 5: 
Because the clinicians collaborate with scientists who take care of all the writing, designing 
and submissions and clinicians are only recruiting the subjects. There is no significant 
intellectual input by these clinicians into the research. Again, if the clinicians had time, 
then they would have better ideas and outcomes by looking into the data they have from 
their patients or ongoing research. Sometimes they forgot even to renew the ethics and 
other important things that we have to remind them about.  
 
Saad: 
When we look at the regulatory framework and the policies that we have for importing 
drugs or new devices, for example, how would you describe its readiness? 
 
Manager 5: 
We might not be ready but then this does not mean that we don’t have the potential. 
Qatar has a potential however I am not sure how focused we are to reach this level. Given 
the time we started, nobody grows this fast specially when it comes to science, we are 
challenging people who have been in the field for more than a century. Hence, we cannot 
compare them with a system (here) that is hardly 30 years old. If we think reasonably, I 
think we are doing well looking at when we started. We can do better of course but it’s 
just that we need more sincere efforts in doing this for Qatar. That is the thing I feel is 
missing here because I see people do it for different purposes but it’s different when you 
write or do something while believing in it. This can be noticed even in resubmitted 
proposals where we can feel how much sincere the investigator was in addressing the 
comments or if they did just for the sake of showing that they did their part by simply 
resubmitting. It requires really hard work to ensure that the money is being awarded to 
the right people because it’s not easy to tell who deserves what. In order to be fair, we 
have to evaluate and reconsider and reconsider and reconsider at different levels until a 
final decision is reached. We did export a lot of science and knowledge to the world 
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thousands of years ago and we have the capacity to do that even now. It’s just the 
confidence and sincerity that is lacking. For example, when I moved to the US, I could not 
be a scientist from day one although I am an experienced physician. The concept here is 
that if you get a grant then that’s it - you are a king - but elsewhere in the world this will 
make you realize that there is so much to do to achieve more. Hence, I would encourage 
the Human Resource (HR) departments to accept only those graduates, mainly Qataris, 
who have worked a couple of years in those systems after graduation so that they have 
practical experience on how research systems function. If they work, then they have to 
complete a full training on the guidelines of research which will add to their experience. I 
think having this strong foundation is very important to realize that these systems are 
controlled by a set of guidelines and policies and not lose to individual controls. We hope 
to have a regional or national control agency like the FDA in future and also having the 
recently established pharma company in Qatar is a good start in this direction. We also 
need to have the regulations for safety and intellectual property of these imports or 
exports because it is a huge responsibility. So, we have the potential and we are taking it 
one step at a time because we can’t leap in science. 
 
Saad: 
You have mentioned few barriers in the course of this interview like maturity of the legal 
system, infrastructure, data access, lack of epidemiological studies, protected time and 
training. Are there any other barriers that you wish to add? 
 
Manager 5: 
I wish I could meet all the investigators here and ask them to open their hearts and be 
more appreciative to what Qatar has given them so that when they give back, they give it 
from their heart, not for the job. Trust me no matter how much you get in your salary it 
can never pay you back the time and effort and health that you lose in reading and 
reviewing research papers or writing them. However, the most rewarding part is when you 
make a difference in someone’s life and you leave a scientific legacy of your own. I think 
that the researchers should work with this mentality that they will leave behind a science 
that will benefit the patients and the future generations. I don’t see this now 
unfortunately, there could be but very few I guess however when we reach to that level, 
we will definitely make a difference. After 10 years of investment, we have the money, a 
fairly good infrastructure, partially developed legal framework but the only think we need 
is sincere efforts.  
 
Saad: 
Do you think that the outcomes of these projects throughout the previous years have been 
successfully transformed into patient care or national programs? 
 
Manager 5: 
It depends on the areas where we invested. For example, we didn’t invest much in 
infectious diseases or reproductive health because the priority was always to diabetes, 
cancer and genetic diseases like autism. We got tangible outcomes, for example, in 
prevalence of autism. For the first time now, we know how many children are suffering 
from autism and this should have been done years ago. Once you know the size of the 
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problem, it is easier to act upon it and address it scientifically and cost-effectively. I think 
it’s too early to assess if we have made any difference or not because we just started and 
most of the projects are ongoing but I can see that we are on the right track. We know the 
problem now so we can act on it but how long does it take to make a difference depends 
on our sincerity and intentions. The intentions are good and Allah says that good 
intentions are always rewarded. Sidra is also a good addition to the clinical research and 
we have high expectation from them as well. However as of today, all what we have is 
mostly data but no drug or device that we can say is made in Qatar. This is not a weakness 
at all because as I said, we are in the early stages because the average timeline to reach is 
12-15 years and we barely started ten years back. We highlighted the gaps and need to 
work on them but so far, we are in the right track. We have many great researchers who 
we can rely on since they are already trained rather than wasting resources on training 
them here – of course the case is different for Qataris where training is necessary to build 
local capacity. 
 
Saad: 
Do you have anything else that you think could add to the topic that I am researching? 
 
Manager 5: 
I would just pray for you to make it happen. It is a very nice concept and right to the point 
and something that was supposed to happen long ago. I hope you continue your PhD to 
cover the researcher’s aspect and compliment both views on the barriers. Your research 
may improve the whole system and I pray it does. We need to change many things in the 
system and it has to be evidence based and your study is what will make it evidence based.  
 
 
** The interview is concluded by thanking the interviewee ** 
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Manager 6 
** The interviewee is welcomed to the interview and briefed about the study ** 
 
Educational Background: Administrative 
 
Age: Less than 50 
 
Saad:  
Could you please tell me about your role in the clinical research leadership at your 
institution? 
 
Manager 6: 
My role is in the research governance and operations. It entails basically the management 
of research operations in terms of operation sides including financials, procurements, 
services, managing day to day activities of the labs and regulatory aspects of the biosafety 
committee. Recently there has been a restructuring and all of this is renamed to research 
services. The research services now include the governance, contracts, regulatory and 
grant management.  
 
Saad: 
How many years have you been in this role? 
 
Manager 6: 
I have been in that role for about 3 years. 
 
Saad: 
How would you describe the support for clinical research in Qatar? 
 
Manager 6: 
The support in general, compared to my last 23 years in US before joining here, is very 
generous in terms of resources, finances, equipment, supplies, facilities – it’s all A++ and 
top notch in these terms. 
 
When it comes to the regulatory side, it’s very primitive and in the beginning of its 
formation and a lot of work needs to be done for research on human subjects and clinical 
trials. I think there is a gap in a lot of regulatory and governance requirements. The MOPH 
research department has been very active and tried to engage us in forming these 
regulations and understating how to manage massive patient data, bio-samples, biobanks 
etc. but I think there is a lot to go to be worldwide benchmarked. 
 
When it comes to return on investments, we need to understand how much we are getting 
out of the generous spending. I honestly believe there is a major gap in understanding our 
KPIs and how do we measure this return on investment – is it just number of publications? 
Or translation to bed side and how it impacted patient care? There are types of researches 
that are directly related to the patient care and mostly found in the academic hospitals and 
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tie the bench to bed so that connection has to be made. In my humble opinion as an 
operations manager, I think this gap exists and the link is not there. There are many 
discussions about innovations, personalized medicine and millions are invested into it but 
the tangible outcomes are missing. It could be just the beginning but there is a lot that 
could be done to expedite that path mainly from the operations and regulatory 
perspective. We don’t need to reinvent the wheel as we can simply build on the processes 
of other systems and start from there instead of reinventing everything from scratch. To 
summarize research in Qatar, and not Sidra specifically, it’s like you bought spare parts of a 
Ferrari but then they are only parts. So, if I want to go downtown, I need a car that will 
take me there not the spare parts but then you have to look how you can assemble the 
parts into a super car. Depreciation of medical and research equipment is 20% per annum 
compared to 10% in other industries so are we fast enough to utilize the investments we 
made or is the plan to keep pouring more and more into latest equipment without actual 
utilization. It is a dilemma worldwide on how to get return on investment but in developed 
countries it is brought back in the form of start-ups, venture capital, biotechnical industry 
where you discover a technology or a drug that pumps millions or even billions back into 
the system. It takes 18 years to develop a medication and put it on the shelves but once it 
does it generates billions. They have a history of doing that in the developed countries and 
they have many in the pipeline so every year something new is in the market that 
generates billions.  
 
Here we see a lot of redundant work but no focused areas. We cannot be good in 
everything; no institution is good in everything. We have to define our trajectory, mission, 
vision to be fitting into the needs of the country. We have all of these things in paper but 
not in the reality. We have to incentive institutions to be aligned with the country’s vision 
and focus for research. Research in country has been going on for at least 10 to 15 years 
now but when is the real assessment of where it’s going? There should be a benchmarking 
every 10 years at least of where we are going when it comes to research outcomes and 
areas of focus. There has to be a single body at the country level that does these 
assessments. Right now, we are working as silos with redundant equipment, redundant 
budgets, redundant contracts but then the spending should be based on a long-term 
strategy. For example, if we look at the investment in the infrastructure like highways, 
sewage systems etc., these are long term investments because they will last for at least 
100-120 years. Likewise, if we look at research, there are areas that take you on the long 
run. There are infrastructures that you can use today and after 100 years but there are 
other infrastructures that you can “flash” or “firework” now but then it’s a very costly 
short-term investment.  
 
The problem with the leadership here is that we have the best scientists but appointed as 
strategists but then they don’t fit in this role. The best physicians not necessarily be the 
best managers of a hospital because a physician who is good in medicine only is different 
than a physician who has studied management. This dilemma exists not only in Qatar but 
elsewhere in the world that technical people when promoted into leadership without 
actual training for that post will eventually create disasters or move in a very slow pace 
until they learn by doing.  
(a side discussion about MORALE curve) 
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So, it’s not about the work someone is doing or the funding they get because given the size 
of Qatar, we can’t afford to work in silos but instead as one focused system.  
 
Saad: 
I think this is possible given the geographical size of Qatar and the fact that all institutions 
are under a single regulatory authority. 
 
Manager 6: 
Yes, but this is where we differentiate good leaders and bad leaders. I use the example of a 
street in Jordan where there are 8 shops side to side selling falafel but only one of these 8 
shops will have customers lined up until midnight. The raw material is same but the way 
you deal with it makes all the difference. So, we can have the best equipment, best 
researchers and best facilities but if we have a paper mentality to manage these, then that 
is a problem. Not a single health institution in Qatar uses prescriptive analytics in 
healthcare which means that we are using basic analytics for the billions of dollars invested 
in the top-notch facilities. If we run those analytics and generate massive data, this would 
then cause experts from Harvard and MIT to come and work here because we would be 
sitting on a gold mine of research data. The Qatar Genome Project is a good example for 
this concept because having this data is the next billion-dollar medication. We have to be 
clear on the management of this asset whether we do it by scientists or business 
innovators.  
 
Saad: 
You referred to the significant funding that is being invested but then there are other 
opinions that the expected outcomes from this funding is not realistic. How would you see 
that? 
 
Manager 6: 
No that is not true. If you visit a lab in NIH, it is merely a booth and 50 people share one 
piece of equipment so you can’t compare it with here. If you talk about salaries, we have 
the highest else they wouldn’t be here. So, I can guarantee you it’s not the salaries or the 
science – then what’s missing? If the question would be how to attract scientists then I 
would agree to some extent but not funding because there is enough money for research 
but then the question is if you are building an infrastructure or a flashy firework like I said 
before.  
 
Saad: 
I have been through all the clinical research institutions in Qatar as a part of this study. I 
am not sure how things are managed at your institution but other institutions have a 
budget for research but then there are several obstacles in using that fund so its not used.  
 
Manager 6: 
This takes us back to the same question about who is managing – scientists or managers. 
These are all operational issues and if you have the right manager who ensures that all 
obstacles are removed, there will be progress. So, it’s not about the funds you have but 
about how it is managed and how you have the right person in the right seat based on 
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their qualifications and skills. In most cases here, there is a mismatch where we place the 
right person in the wrong seat. When an institution fires 500 people and I am about to hire 
500 people every 2 years, then there is something fundamentally wrong in the 
management system. Is it a silo called HR? Or the scientists? Or the management? There 
should be someone to look at all these silos together to make a smart decision. Sometimes 
you need to invest money to save money but here that is difficult to convince them with 
this idea of investment to save. There are millions of papers written on how to manage 
when an economy is down or a company is suffering financially – it’s not something new to 
be studied. Having been in so many institutions in my career, I can tell you. The only thing 
missing for research across Qatar is proper management and oversight. Here, I am 
referring to the overall cross-institutional strategic management of the research pot. 
 
Saad: 
How would you describe the overall attitude of clinicians towards research at your 
institution? 
 
Manager 6: 
If you remember the morale curve we discussed earlier, I would say that 60% are 
disengaged because of all the barriers and obstacles and the 40% are still continuing 
because I would say they are positive thinkers.  
 
Saad: 
Don’t you think that this percentage of the disengaged researchers would then become a 
barrier/ burden to the system? 
 
Manager 6: 
Only if we leave them that way but if the leadership is working closely with them to ensure 
they are re-engaged, then they won’t become a barrier. Again, there are many studies 
about inexpensive efforts that could increase employee morale across hospitals but then if 
the leaders are not going to listen or understand these problems, then it will lead to 
problems. This dilemma is worldwide – I am the boss I know everything. The first thing 
they need to realize is that they don’t know everything because it is the front liners who 
know the problems and hence, they need to be engaged in the decision-making process 
and the strategic management of the institution. I can see that when it comes to the 
scientists and researcher, we are bringing in top notch quality but then the people who run 
the operations for these scientists are not very high level. So, we need restructuring but 
restructuring not necessarily means removing the people but investing in them by further 
training and coaching. Hence, they need to realize that world class scientists or clinicians 
do not really make the best managers, unless they have been trained for that role. 
 
Saad: 
So, talking about the barriers, you mentioned one of them is the management? 
 
Manager 6: 
No, it’s not the management actually but the leadership. Management means you give 
them a list of tasks to complete and they will do it. We have very good managers around 
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here. Leaders need to identify the ecosystem, strengths, weaknesses and how people from 
country A and B should be treated differently based on their individual characters. There 
are books and studies on emotional intelligence in management and how to create an 
organizational culture. It’s not about putting values on the wall or website but about how 
they are implemented and practiced in the organization.  
 
Saad: 
Let’s start listing other barriers to conduct clinical research in Qatar. 
 
Barriers Discussion 
Regulations 
Regulations are primitive and need a lot of 
development 
No clear KPIs 
No clear KPIs or benchmarks, universal 
mission and vision, alignment to that 
mission and vision, unstable leadership to 
support the mission and vision. 
Lack of measures No balance score cards or added value 
Data management 
Absence of data retention, use and 
management 
Leadership 
All barriers and obstacles are traced back to 
leadership 
Operational barriers HR and finance related issues 
Lack of understanding of governance roles 
The management depends on the feedback 
of the “violators” to review the 
performance of the governance officers. 
Instead of measuring the number of tickets, 
violations stopped and corrective actions, 
they will measure the satisfaction of the 
violators against the officer. 
 
Saad: 
When you said about the frequently changing management, is it something specific to here 
or have you seen this during your professional experience outside? 
 
Manager 6: 
I started the health care systems engineering department which was only one of the 5 in 
the whole US and by the time I left there were 20 institutions applying the same concept 
across the US. Here, I have been trying to convince them for the last 5 years with no 
success at all although I can confidently tell you that the entire country does not have a 
single health care engineer doing something as of now. So, going back to your question, 
institutions do change their strategies but they do that in a systematic way. The university 
where I was used to be a pure engineering college that has nothing to do with healthcare 
but they changed their strategy systematically to include healthcare engineering through 
our department. Now, after 5 years since I left them, they have a vice president for health 
management and a whole department for health. So, these changes are a system of checks 
and balances and not a one-man decision. It does involve risk but then it’s a well calculated 
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risk. For example, Warren buffet had a company and its manager decided to invest $300 
million into a venture which eventually failed. Warren then call this manager to his office 
and the latter believes that it is the end of his journey in this position but instead warren 
asks him about his future plans for new programs. Surprised and shocked, the manager tell 
warren that he was expecting to be fired and Warren tells him “didn’t you take all the 
precautions before starting the venture?”. Warren replies that” as long as we learn the 
lessons from this, we are in the business of taking risks.” This manager gets so motivated 
and committed that he created the one billion industry that contributed to most of Warren 
Buffets wealth. So, investing or taking a risk is not a bad thing but as long as its well 
calculated.  
 
Saad: 
When benchmarking, do you think that we should benchmark ourselves with the elite or 
be realistic and match with someone on a moderate level? 
 
Manager 6: 
Well if you are spending similar to the elite, equip more than the elite, supply more than 
the elite and you have open cheque but then expect less than the elite then, with all due 
respect, something is wrong. We should always set the vision to the stars so that even if 
we don’t reach there, we still reach somewhere high but if your target is to benchmark 
with middle east, you will end up even less than that. The question that I should be asking 
you is “what is missing for us to reach there?” and you will not find an answer because we 
have everything including scientists, equipment, safe environment and diverse research 
subjects. In the beginning there could be some problems but then why do I have to set on 
this long path when I can use a super expedited path by learning from what others have 
already done so far. So, going back, it always traces back to the leadership. 
 
Saad: 
How do you see the translation of the research outcomes into patient service or national 
programs? 
 
Manager 6: 
For patients, it is similar to the politicians who have to show them actual spending as 
infrastructure like roads, bridges, services etc. but if they are building bridges to nowhere, 
the public will not favor them in the next elections. In the spectrum of research, you have 
basic at one end and the clinical trials and studies like surveys of the other. The strategic 
question here is on what side of this spectrum should we focus? Is it academic research 
which usually generates papers and add to the international literature or the clinical part 
where the actual translational and clinical research is happening? That is the right question 
and I am not the person to answer it but I would love to see it touch the patients. When 
you come to Sidra, it is supposed to be a facility where you can do all the fancy stuff for 
which you otherwise pay millions of dollars outside for your patients every year. 
 
Saad: 
Taking into consideration the barriers you identified and the positive aspects of the 
system, how would you describe the readiness of the system here for clinical research? 
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Manager 6: 
I think it’s not the right question to ask. The right question that I would like to answer is 
what does it take Qatar and my institution in particular to be an elite. I believe it’s just the 
last mile – the leadership. 
 
Saad: 
Why is it the last mile and not the first? 
 
Manager 6: 
Because we have all the other elements like scientists, fund and infrastructure. We have 
the parts of the Ferrari, we know its name, we have the manual, we know how it could be 
assembled and all we lack is the person who has the right skills to assemble these parts 
and make it run. So, it’s been a long mile but it’s the last mile. 
 
 
** The interview is concluded by thanking the interviewee ** 
 
